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Abbreviations 
ACSF   artificial cerebrospinal fluid  
AEDs   anti-epileptic drugs 
AMPA   α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ANOVA  analysis of variance 
AQP4   aquaporin 4 
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BBB   blood brain barrier 
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CNS   central nervous system 
Contr.   control 
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Cx30   connexin 30 
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DAMPs  damage associated molecular patterns 
DG   dentate gyrus 
DH   double hit 
DIC    differential interference contrast  
DNA   deoxyribonucleic acid 
EAAT   excitatory amino acid transporter  
eGFP   enhanced green fluorescent protein  
EFSs   experimental febrile seizures 
ERK   extracellular signal-regulated kinase 
FSs   febrile seizures 
GABA   γ-Aminobutyric acid 
GFAP   glial fibrillary acidic protein 
GΩ   gig ohm 
GS   glutamine synthetase 
HET   house for Experimental Therapy of Universitätsklinikums 
HS   hippocampal sclerosis 
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IKK   IκB kinase 
IL-1β   interleukin 1β 
IL-6   interleukin 6 
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Introduction 
 
 
11 
 
1 Introduction 
1.1 Nervous system 
In vertebrates the nervous system consists of two parts: central nervous system 
(CNS) which is composed of brain and spinal cord; and peripheral nervous system 
that comprises the neuronal network outside of the brain and spinal cord. The brain 
is located in the head, where it is protected by the meninges and skull. It is 
composed of five parts: telencephalon, diencephalon, mesencephalon, 
metencephalon and myelencephalon. It also contains cavities, which are called 
ventricles, and these ventricles are filled with cerebrospinal fluid (CSF). These 
ventricles are connected with each other and also with the spinal cord.  
 
The brain tissue is composed of different cell-types, e.g. neurons, glial cells, 
endothelial cells, etc. In murine brain around 7.1x107 neurons are present, these 
neurons form around 1011 synapses with each other in a complex network 
(Herculano-Houzel et al., 2006). Almost 65 % of the mouse brain is composed of 
glial cells (Allen and Barres, 2009). In the brain two different types of nervous tissues 
can be distinguished optically: highly myelinated white matter and less myelinated 
grey matter which also contains unmyelinated neurons. 
 
The different brain regions can be subdivided into discrete parts which have specific 
functions. This study is focused on the hippocampus, which will be explained in 
detail below. 
 
1.2 Hippocampus 
The hippocampus is located in the medial temporal lobe and is part of the limbic 
system. Its name ‘Hippocampus’ has been derived from the Greek word for 
seahorse, because of its structural resemblance to seahorse. It is a paired structure 
with a hippocampus in each hemisphere. It is subdivided into several regions: Cornu 
Ammonis (CA) 1 to CA3 and the dentate gyrus (DG). The CA region consists of 
several layers: stratum (st.) pyramidale (pyr.), st. oriens (ori.), st. radiatum (rad.) and 
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st. lacunosum moleculare (lm.). The st. pyr. contains the somata of excitatory 
pyramidal neurons, these neurons stretch their axons into the st.ori. The dendrites of 
these neurons extend into the st. rad. The other layers contain inhibitory 
interneurons and several types of glial cells. The dentate gyrus has a typical V-
shape. It contains the neuronal granular cell layer. The inside of this layer is called 
hilus and the outer layer is called st. moleculare (Amaral and Witter, 1989). The 
subgranular zone (SGZ) is the innermost granule cell layer, it is one of the 
neurogenic niches in the adult brain, and it contains neural stem cells which can 
differentiate into new neurons (Seri et al., 2001). 
 
 
Figure 1.1 Anatomy and neuronal circuit of the hippocampus. In the small inset 
the localization of the hippocampus in the murine brain has been illustrated. The 
synaptic input from the entorhinal cortex reaches at DG; from DG it is sent via mossy 
fibers to the CA3 pyramidal neurons, from CA3 it is transferred by Schaffer 
collaterals to the CA1 neurons, CA1 neurons signal back to the entorhinal cortex. 
LPP, lateral perforant pathway; MPP, medial perforant pathway. From Deng et al., 
2010. 
 
In the hippocampus the neuronal circuit is a trisynaptic excitatory pathway as shown 
in figure 1.1. From the entorhinal cortex the synaptic input arrives in the DG and from 
DG it is propagated by mossy fibers to the CA3 pyramidal neurons. From CA3 
neurons Schaffer collaterals project to the dendrites of CA1 pyramidal neurons in the 
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st. rad. From the CA1 neurons the signal is sent back to the entorhinal cortex (Deng 
et al., 2010). 
 
The hippocampus plays a vital role in learning and memory. Long lasting changes in 
synaptic transmission on the cellular level are called synaptic plasticity, and these 
changes have been found to be correlated with memory formation. Long lasting 
changes in synaptic strength have been observed in rodents which were exposed to 
hippocampus related learning tasks (Martin and Morris, 2002). Furthermore, the 
hippocampus has been found to be involved in emotional behavior, and the 
emotional status has been shown to influence adult neurogenesis in the SGZ (Deng 
et al., 2010). In addition, reduced adult neurogenesis impairs learning, therefore, the 
integration of newly formed neurons is essential for memory formation (Martin and 
Morris, 2002). 
 
1.3 Glial cells 
In the central nervous system neurons are responsible for the fast and accurate 
transmission of signals and stimuli. However, these cells cannot perform their 
function without the support of glial cells. The term "glia" was introduced by Rudolf 
Virchow (1821-1902) in the mid-19th century and is translated from the Greek as 
"glue". This idea was based on the conviction that these cells are exclusively 
responsible for supporting and holding the neurons. Today, we know that the glial 
cells contribute much more to the neuronal physiology than first thought. For 
example, a rapid information transmission without the oligodendrocytes would be 
unthinkable, because they form the myelin sheath and thus insulate the axons 
electrically. Microglia combined with astrocytes form the innate immune system of 
the brain and both of these cell types are responsible for the protection against 
infection. Thus, each cell type has an important function in the brain and is therefore 
essential for homeostasis. 
 
Basically, the glial cells are divided into two groups: microglia and macroglia. 
Macroglia are further subdivided into different cell subtypes: NG2 cells, 
oligodendrocytes and astrocytes. 
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1.3.1 NG2 cells 
The term NG2 is derived from nerve / glial antigen 2, a proteoglycan expressed on 
the surface of these cells. Originally, NG2- positive cells were viewed as precursors 
of oligodendrocytes (oligodendrocytes precursor cells, OPCs) (Polito and Reynolds, 
2005). However, increasing evidences support that these cells represent an 
independent glial cell type (Nishiyama et al., 2009) and it has been widely accepted 
as a fourth major glial cell type comprising 2-8 % of the cells in adult CNS, distinct 
from oligodendrocytes, astrocytes and microglia (Nishiyama et al., 2009). Also, it has 
been shown that NG2 can differentiate into astrocytes (Zhu et al., 2011), which 
suggests that the fate of NG2 cells is not determined toward oligodendrocytes 
lineage. In 2000, Bergles and colleagues provided evidence for the existence of 
functional synapses between neurons and glial cells in the hippocampus (Bergles et 
al., 2000). The postsynaptic glial cells were identified as NG2-positive OPCs. 
Additional properties of these cells included the expression of α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) and γ-aminobutyric acid (GABA) receptors 
(Bergles et al., 2000; Bergles et al., 2010), lack of gap junction-mediated coupling, 
and the absence of glutamate transporters (Matthias et al., 2003). 
 
1.3.2 Oligodendrocyte 
As already mentioned before, the oligodendrocytes form an insulating layer around 
the axons of the neurons in vertebrates. This insulating layer is called myelin sheath 
and consists of the complex and lipid-rich myelin. This insulation is interrupted at 
nodes of Ranvier and primarily accelerates the signal transduction, because the 
action potentials can only arise at the nodes of Ranvier, called "saltatory conduction"  
(Huxley and Stampfli, 1949). The myelin sheath is probably not only the electrical 
insulation, but has also neuroprotective and neurotrophic effects (Nave, 2010; 
Wilkins et al., 2003). Demyelination and thus an impaired signal transduction takes 
place during some neurodegenerative diseases such as multiple sclerosis or acute 
disseminated encephalomyelitis (Love, 2006). In this case, the immune system and 
the overproduction of cytokines such as tumor necrosis factor α (TNF-α) and 
interferon play a central role (Ledeen and Chakraborty, 1998). Oligodendrocytes also 
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express AMPA, kainate and N-methyl-D-aspartate (NMDA) receptors in addition to 
ATP-gated P2X7 receptors (Bradl and Lassmann, 2010). 
 
1.3.3 Microglia 
Microglia represent the immune system of the brain (Kreutzberg, 1996). It is the only 
cell type in the brain that is not derived from the neuroectoderm. These are 
phagocytic descendants of the mesoderm, which migrate into the brain during 
embryonic development (Vilhardt, 2005). Microglia promote neuronal survival, 
regulate generation of neurons and oligodendrocytes, play a vital role in the 
processes involved in learning and memory, in addition to supporting synaptic 
plasticity and cognitive function (Eyo et al., 2016). Interestingly, the morphology and 
density of microglia varies as a function of their localization in the brain (Lawson et 
al., 1990). Microglia density in the healthy brain is highest in the hippocampus 
especially in the CA1 and DG (Jinno et al., 2007). 
 
In the resting state, microglial cells have a ramified morphology, a small cell soma 
with fine extensions. By using these active motile appendages they continuously 
monitor their surroundings without disturbing the neural integrity (Davalos et al., 
2005; Dibaj et al., 2010; Nimmerjahn et al., 2005). The surface of these appendages 
is decorated with numerous receptors for chemokines, cytokines, and also receptors 
from the complement family (Kettenmann et al., 2011). A characteristic feature of 
microglia is its activation at a very early stage after an injury or infection (Cherry et 
al., 2014; Rock et al., 2004). The cells respond not only to gross violations of the 
structural integrity, but also to more subtle changes in the environment, such as  
variations in the ion balance (Kreutzberg, 1996). Microglia detect pathological 
changes in the tissue, and become activated. Microglia activation is characterized by 
increased proliferation, morphological transformation, the release of various types of 
pro-inflammatory cytokines such as Interleukin 1β (IL-1β), Interleukin 6 (IL-6), TNF-α 
and / or chemokines (Banati et al., 1993; Smith et al., 2012; Vezzani et al., 2008). In 
addition to the neutralization  and removal of the invaders, toxic substances, cellular 
debris and apoptotic neurons (Ahlers et al., 2015) by phagocytosis (Sierra et al., 
2013), microglia can act as antigen presenting cells (O'Keefe et al., 2001). They are 
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also responsible for the elimination of synapses, for example during postnatal 
development (Tremblay et al., 2011). 
 
Besides their inflammatory response to damage associated molecular patterns 
(DAMPs) and pathogen associated molecular patterns (PAMPs) (Heneka et al., 
2014; Town et al., 2005), it has been revealed that microglia also exchange 
information with neurons. Microglia physically interact with neurons, modulate 
neurotransmission (Eyo et al., 2016), regulate synaptic activity (Ji et al., 2013), and 
actively participate in remodeling synaptic architecture (Tremblay et al., 2010). It has 
been suggested that microglia modulate neuronal activities (Bechade et al., 2013; 
Eyo and Wu, 2013). On one hand, receptors for cytokines such as IL-1β can be 
found on the surface of nerve cells, these receptors exert an influence on neuronal 
activity (Viviani et al., 2003), while on the other hand, the microglia express the 
receptors for different neurotransmitters, which may cause inflammatory or 
neuroprotective outcomes depending on the situation (Pocock and Kettenmann, 
2007). 
 
During neuro-pathophysiological conditions microglia can play both neuroprotective 
as well as neurotoxic roles depending on the situation (Ransohoff and Perry, 2009). 
Activated microglia have been observed in animal models of epilepsy (Avignone et 
al., 2008; Eyo et al., 2014) as well as in the brain tissue obtained from temporal lobe 
epilepsy (TLE) patients (Beach et al., 1995). Activated microglia release 
inflammatory cytokines such as IL-1β (Smith et al., 2012; Vezzani et al., 2008) and it 
has been shown that IL-1β promotes febrile seizures (FSs) (Dube et al., 2005; Heida 
et al., 2009; Yu et al., 2012). Furthermore, in humans polymorphism in the IL-1β 
gene has been found to increase the susceptibility for FSs (Kira et al., 2010; Virta et 
al., 2002a). 
 
1.3.4 Astrocytes 
The name ‘astrocyte’ is derived from their typical star-like morphology. These cells 
have a ramified structure with fine processes. The main component of intermediate 
filaments of all astrocytes is the glial fibrillary acidic protein (GFAP), which is 
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expressed in adult astrocytes (Brenner et al., 1994). A distinction is made between 
the protoplasmic astrocytes, especially in the gray matter and the fibrous astrocytes, 
which are found mainly in the white matter. The fibrous astrocytes have an elongated 
shape and are often aligned parallel to the axons. However, the protoplasmic 
astrocytes are characterized by a more compact form, which is caused by a very 
dense network of lateral branches that arises from the thicker primary projections. 
With the help of different staining methods, it has been found that protoplasmic 
astrocytes are organized into domains (Bushong et al., 2002; Ogata and Kosaka, 
2002). In this case, a cell occupies a polyhedral shaped space, so that all synapses 
and blood vessels in this area are in contact with one astrocyte. Therefore, an 
astrocyte can contact several thousand synapses (Clarke and Barres, 2013; Halassa 
et al., 2007). The domains of adjacent cells slightly overlap only at the outer borders. 
This phenomenon was observed in both murine and human astrocytes in the cortex 
and hippocampus (Oberheim et al., 2006). However, there is also evidence that the 
size of astrocytes and their degree of overlap are not constant, but can change 
during the course of life (Grosche et al., 2013). Studies have shown that 
protoplasmic astrocytes are approximately 2.5 times larger in diameter and have a 
10 times denser network of main extensions in humans than those in rodents 
(Oberheim et al., 2009). Also, the ratio of astrocytes per neuron increases with 
increasing brain complexity (Allaman et al., 2011; Nedergaard et al., 2003). In the 
human brain astrocytes are the most common cell type, they make up around 80 % 
of all the cells in the brain (Kettenmann and Ransom, 1995). The fact that the ratio 
between glial cells and neurons, called ‘Glia index’ increases with the degree of 
development of the living organism (Nedergaard et al., 2003) can be the first 
evidence that supports the involvement of astrocytes in information processing.  
 
The astrocytes form end feet at the extensions that have contact with the blood 
vessels. This structure can be regarded as a special compartment, with an increased 
expression of certain proteins such as aquaporin 4 (AQP4), inwardly rectifying 
potassium channel (Kir) 4.1, glucose transporter and connexin43 (Cx43) (Crunelli et 
al., 2015; Wang and Bordey, 2008). Through their end feet enwrapping blood 
vessels, astrocytes take up water and metabolites from the blood and release 
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excess water, ions and toxins into the blood (Nedergaard et al., 2003; Strohschein et 
al., 2011). Astrocytes provide a link between the capillaries and neurons (Nagelhus 
et al., 2004; Simard and Nedergaard, 2004), and thus play a central role in the 
neuro-metabolic coupling. Increased neuronal activity triggers Ca2+ release in 
astrocytes. This leads to the release of vasoactive substances from astrocytes that 
regulate local blood flow (Attwell et al., 2010; Takano et al., 2006). This enables the 
supply to the neurons to be adjusted according to the actual neural activity. Of 
course, an increased neuronal activity requires more energy and thus reshapes 
astroglial metabolic networks (Escartin and Rouach, 2013).  
 
The processes of astrocytes often surround and envelop synaptic connections and 
form the so called tripartite synapse (Nedergaard and Verkhratsky, 2012; Pannasch 
and Rouach, 2013). The astrocytes not only take up K+ ions and neurotransmitters 
such as glutamate (Coulter and Eid, 2012) and GABA but are actively involved in the 
processing of information. They can receive signals from neurons and react to it 
(Clarke and Barres, 2013) by releasing so-called “gliotransmitters”, including 
glutamate, D-serine and ATP (Harada et al., 2015), and thus can influence neuronal 
activity (Bazargani and Attwell, 2016; Haydon, 2001; Volterra and Meldolesi, 2005). 
In fact, on astrocytes similar receptors can be found as on neurons; depending on 
the brain region, the receptors can be for glutamate, purine, GABA, noradrenaline, 
histamine and others (Agulhon et al., 2008; Dani and Smith, 1995; Martin, 1992). 
Thus, astrocytes are capable of receiving signals from the neurons. Most of these 
are metabotropic receptors that have a connection to second messenger systems, 
including phospholipase C, inositol trisphosphate (IP3), Ca2+ and cyclic adenosine 
monophosphate (cAMP) (Verkhratsky et al., 1998; Volterra and Meldolesi, 2005). It 
has been shown that in acute hippocampal slices neural activity at the mossy fiber 
CA3 synapses increases the intracellular Ca2+ concentration ([Ca2+]i) and triggers 
interastrocytic Ca2+-waves (Dani et al., 1992). This applies not only to glutamate, but 
also similar Ca2+ signals in the hippocampus can be triggered by the release of 
acetylcholine (Araque, 2008). Further analysis showed that these signals can be 
divided into two groups: 1) Ca2+ oscillations, defined as recurrent increases in [Ca2+] i 
within a cell and 2) Ca2+ -waves, defined as radially propagating increases of [Ca2+] i 
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emanating from a cell and then spreading to neighboring cells (Berridge et al., 1998). 
In addition to glutamate, GABA and ATP can trigger Ca2+ oscillations (Dani and 
Smith, 1995). The astrocytes are not only able to receive signals from the neurons 
but also Ca2+ signals in astrocytes may in turn cause the release of neuroactive 
substances in the extracellular space. These include transmitters, eicosanoids, 
steroids, neuropeptides and growth factors (Araque, 2008; Araque and Navarrete, 
2010; Haydon and Carmignoto, 2006; Martin, 1992). One possible function of this 
ability of astrocytes to influence neuronal activity is the synchronization of large 
neuron clusters. If one considers that the processes of a single astrocyte contact 
thousands of synapses and that the astrocytes form the largest network in the brain, 
the potential of this cell type is evident. 
 
Since astrocytes are coupled to each other via gap junction channels that are 
composed of connexins (Cxs) (Dermietzel et al., 2000; Giaume and McCarthy, 1996; 
Gosejacob et al., 2011; Kielian, 2008), they make up the largest network in the brain. 
In the hippocampus this network is formed during early postnatal development 
(Schools et al., 2006). The astrocytes are responsible for the supply of nutrients to 
neurons, removal and recycling of glutamate from the synapses (Coulter and Eid, 
2012), and the buffering of extracellular K+ ions (Kofuji and Newman, 2004; 
Steinhäuser et al., 2012; Steinhäuser et al., 2016). The functional interastrocytic gap 
junctional coupling (IGJC) plays a key role in these processes. The gap junction 
channels are permeable to substances smaller than 1.2 kDa and are regulated by a 
number of factors including pH, Ca2+ concentration, intracellular voltage differences 
and inflammatory mediators like IL1-β (Meme et al., 2004; Meme et al., 2006; 
Rouach et al., 2002a). 
 
Studies performed on sclerotic hippocampi from epilepsy patients and experimental 
animal models have shown that astrocytes are uncoupled in the last chronic stage of 
the disease (Bedner et al., 2015). During neuronal activi ty K+ ions are released. 
These ions must be removed quickly, otherwise they lead to a sustained 
depolarization of the membrane and thus can affect the activity of ion channels, 
receptors and transporters (Steinhäuser and Seifert, 2012). During a pathologically 
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increased neuronal activity, the extracellular concentration of K+ ions can increase 
from 3 mM to 10-12 mM (Heinemann and Lux, 1977; Steinhäuser et al., 2012). The 
activity of Na+ / K+ pumps  present in the cells is not sufficient to rapidly transport as 
much K+ ions into the cells. Two additional mechanisms for K+ buffering have been 
described, the Na+ / K+ / 2Cl cotransporter and the "spatial buffering" (Kofuji and 
Newman, 2004; Steinhäuser et al., 2016). The former is likely to play a minor role. 
Besides, intracellular K+ accumulation results in water influx and cell swelling. The 
concept of spatial buffering, however, states that astrocytes take up the excess K+ 
ions in regions of high neuronal activity, and carry it away by the astrocytic network 
to regions of lower K+ ions concentrations, where it is then released into the 
extracellular space (Kofuji and Newman, 2004; Steinhäuser et al., 2012; Steinhäuser 
et al., 2016). Uptake and release of K+ ions takes place here by Kir4.1. The 
effectiveness of the K+ buffering depends on the proper function and distribution of 
K+ channels, water channels AQP4 and IGJC (Hibino et al., 2010; Reimann and 
Ashcroft, 1999; Steinhäuser et al., 2012; Steinhäuser et al., 2016). 
 
Transporting the metabolic substrates such as glucose, lactate and amino acids to 
the neuron is needed not only for the energy supply, but also for the synthesis of 
neurotransmitters such as GABA and glutamate. After the neurons have released 
neurotransmitters at synapses, these are taken up by astrocytes from the 
extracellular space (Coulter and Eid, 2012). Here a special role is played by the 
glutamate transporters expressed in astrocytes, because glutamate is potentially 
neurotoxic and is mainly taken up by astrocytes (Coulter and Eid, 2012). These 
transporters are very effective and keep the extracellular glutamate concentration in 
the nM range (Danbolt, 2001). A down-regulation of astrocytic glutamate transporter 
leads to an accumulation of the neurotransmitter in the extracellular space and thus 
creates a continuous excitation of neurons, which can ultimately lead to their death 
(Herman and Jahr, 2007; Jabaudon et al., 1999; Sah et al., 1989). Indeed, 
dysfunction of glutamate transporters, named excitatory amino acid transporter 
(EAAT) 1 and EAAT2, were observed in pathological conditions, including epilepsy 
(Seifert et al., 2006). Another mechanism that leads to the accumulation of glutamate 
in the extracellular space and is likely to contribute to the development of epilepsy is 
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the loss of activity of the enzyme glutamine synthetase (GS) in astrocytes (Coulter 
and Eid, 2012; Eid et al., 2008; Nedergaard et al., 2003; Norenberg, 1979; van der 
Hel et al., 2005). This enzyme converts glutamate to glutamine in astrocytes, which 
is released into the extracellular space and is subsequently taken up by the neurons 
(Coulter and Eid, 2012). GS deficiency slows down glutamate uptake, leading to 
increased glutamate levels in the ECS. The glutamate-glutamine cycle is essential 
for replenishing the neurotransmitter pool and maintenance of synaptic activity. 
Interruption of the cycle rapidly depletes inhibitory (GABAergic) transmission, while 
excitatory synaptic function is sustained (at least transitionally) due to the higher 
reserve pools of cytoplasmic glutamate (Liang et al., 2006; Robel and Sontheimer, 
2016; Steinhäuser et al., 2016). 
 
It has been suggested that under neuro-pathological conditions, astrocytes can play 
pro-inflammatory as well as anti-inflammatory roles depending on the plethora of 
molecular, cellular and physiological conditions (Sofroniew, 2015). In response to 
traumatic CNS insults, astrocytes undergo biochemical, physiological and 
morphological changes (Wilhelmsson et al., 2006), collectively termed as “reactive 
astrogliosis” (Sofroniew and Vinters, 2010). Reactive astrogliosis has been classified 
into three categories: mild to moderate reactive astrogliosis, severe diffuse reactive 
astrogliosis and severe reactive astrogliosis with compact glial scar formation 
(Sofroniew and Vinters, 2010). Astrocytes interact with other cell types, especially 
fibromeningeal and other glial cells to form complex glial scars in the CNS 
(Sofroniew, 2009). It has been shown that the scars formed by reactive astrocytes 
can have positive affect including repairing blood brain barrier (BBB), limiting 
leukocyte infiltration and act as a neuroprotective barrier (Bush et al., 1999; Faulkner 
et al., 2004; Herrmann et al., 2008). Reactive astrocytes can have both pro- and anti-
inflammatory effect on microglia (Davalos et al., 2005; Min et al., 2006). In response 
to IL-1β astrocytes generate and release vasoactive substances like VEGF, which 
increases BBB permeability and promotes leukocytes infiltration (Argaw et al., 2009; 
Argaw et al., 2012). It has been suggested that brief disruption in the BBB is enough 
to induce focal epilepsy in rats (Seiffert et al., 2004). Under inflammatory conditions, 
astrocytes release inflammatory cytokines such as TNF-α and IL-1β (Dube et al., 
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2010). The inflammatory cytokines depolarize astrocyte which as a result decreases 
K+ and glutamate uptake (Kielian, 2008) resulting in hyperexcitability which can 
promote epileptogenesis.  
 
1.4 Connexins 
For intercellular communication cells are connected via gap junctions. Gap junctions 
allow the transfer of ions and small molecules between the cytoplasm of cells 
bypassing the extracellular space. Gap junctions are composed of Cxs. In human 21 
genes and in mice 20 genes have been identified to encode for Cxs (Sohl and 
Willecke, 2004). In the rodent brain 11 Cxs have been detected. Cxs are named 
based on their molecular mass. Cx43, for instance, has a molecular weight of 43 kDa 
(Sohl and Willecke, 2004). 
 
After and / or during translation Cxs integrate into the endoplasmic reticulum. 
Oligomerization of six Cxs to form a hexameric hemichannel called ‘connexon’ has 
been suggested to take place in a progressive fashion, it starts in the endoplasmic 
reticulum and completes in the Golgi apparatus (Laird, 2006; Musil and 
Goodenough, 1993). Connexons are transported in vesicles via microtubules to the 
plasma membrane. Each Cx protein has two extracellular loops, four transmembrane 
domains, one cytoplasmic loop, one cytoplasmic C- and one cytoplasmic N- terminus 
(see Fig. 1.2b). The transmembrane domains form the wall and pore of the channe l. 
The extracellular loops are involved in cell-cell recognition and docking processes. 
Each extracellular loop contains three cysteine residues which form disulfide bonds 
between the connexons of opposite plasma membranes. When two hemichannels 
from opposing cells come in contact a functional gap junction is formed. 
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Figure 1.2 Gap junction plaque configuration and connexin structure. a) A gap 
junction plaque consists of several hemichannels formed of hexameric connexons. 
Gap junctions are comprised of two connexons connected together from two plasma 
membranes. Gap junctions composed of one Cx isoform are called homotypic or 
homomeric (1), gap junctions formed of connexons where each connexon consists of 
different Cx isoforms are termed as heteromeric (2), gap junctions made of two 
different homomeric connexons are called heterotypic gap junctions (3). (b) Each Cx 
consists of two extracellular loops, four transmembrane domains, one cytoplasmic 
loop, one cytoplasmic C- and one cytoplasmic N- terminus. From Sohl et al., 2005. 
 
Gap junctions formed between cells can be homotypic, heterotypic and / or 
heteromeric intercellular channels. Homotypic or homomeric intercellular channels 
are formed by identical connexons, heterotypic channels are composed of two 
connexons of different Cx composition (Dedek et al., 2006) and gap junctions formed 
from connexons composed of different Cx isoforms (He et al., 1999) are named 
heteromeric gap junctions (see Fig. 1.2a). It has been shown that the combination of 
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the same and / or different Cxs and connexons to form functional gap junctions 
increases the diversity of intercellular gap junctions with a variety of functions and 
adds different physiological properties including permeability, single and multiple 
channel conductance’s states (Goodenough and Paul, 2009). Originally it was 
suggested that small molecules up to 1.2 kDa can freely move through gap junctions 
(Simpson et al., 1977), but later studies suggested selective permeability of gap 
junctions depending on their composition (Kielian, 2008; Mese et al., 2007). The gap 
junctions formed of different Cxs showed similar permeability for ions but displayed 
differences in permeability for larger metabolites and second messengers (Mese et 
al., 2007). Membrane-spanning hemichannels which cannot form gap junctions and / 
or before forming gap junctions can also be functional under different conditions and 
open into the extracellular space resulting in the release of ATP, glutamate, 
nicotinamide adenine dinucleotide (NAD+) and prostaglandin E2, which act as 
paracrine messengers (Evans et al., 2006). Gap junction channels cluster into 
microdomains in the plasma membrane, called gap junction plaques (Gaietta et al., 
2002). A gap junction plaque is a highly dynamic structure which is in a continuous 
process of formation and degradation, where newly formed gap junction channels 
are added to the periphery of the plaque and old channels are removed from the 
center of the plaques (Gaietta et al., 2002) and internalized into pleomorphic vesicles 
called ‘annular junction’ (Jordan et al., 2001). Gap junctions in annular junction are 
then subject to lysosomal or proteasomal pathways for degradation (Falk et al., 
2014). 
 
Cxs are expressed in almost all cell types in the brain, except in NG2 cells.                                                                                                                                                                                                                         
In brain, astrocytes display the highest level of two Cxs, i.e. Cx30 and Cx43 which 
are the major Cxs co-expressed in hippocampal astrocytes (Giaume and McCarthy, 
1996; Gosejacob et al., 2011). In addition to Cx30 and Cx43, the expression of other 
Cxs namely Cx26, Cx32, Cx40, Cx45 and Cx46 have been detected in astrocytes 
(Blomstrand et al., 2004; Dermietzel et al., 2000) which have been reported to play 
compensatory roles (Dermietzel et al., 2000; Scemes et al., 1998). Nevertheless, the 
two Cx proteins Cx30 and Cx43 provide the structural basis for the formation of 
astroglial networks through which intercellular transfer of energy metabolites 
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(Rouach et al., 2008), gliotransmitters, signaling molecules (Harris, 2007), and 
spatial buffering of K+ takes place (Wallraff et al., 2006). 
 
Gap junction communication can be regulated at several levels including 
transcription, translation, post-translational processing like phosphorylation, insertion 
and / or removal from plasma membrane (Kielian, 2008). Furthermore, the 
permeability of gap junctions is regulated by a number of factors including pH, Ca2+ 
concentration, intercellular voltage differences, etc (Rouach et al., 2002a). In many 
studies, inflammation, inflammatory cytokines and mediators have been suggested 
to play a critical role in the regulation of gap junctional communication (Kielian, 
2008). Though astrocytes express both Cx30 and Cx43, the former is more 
important in the thalamus while the latter has been suggested to play the major part 
in gap junctional coupling in the hippocampus (Dermietzel et al., 2000; Gosejacob et 
al., 2011; Griemsmann et al., 2015; Kielian, 2008). It has been shown that IL-1β 
inhibits gap junctional communication in primary human fetal astrocytes which was 
suggested to be caused by the reduction in Cx43 mRNA and protein expression 
(Duffy et al., 2000; John et al., 1999). In similar studies reduction in IGJC under the 
influence of IL-1β and TNF-α has been reported (Meme et al., 2004; Meme et al., 
2006). TNF-α has also been shown to reduce Cx43 promoter activity (Fernandez-
Cobo et al., 1999). Furthermore, TNF-α was found to reduce gap junction coupling 
via Cx43 phosphorylation (Haghikia et al., 2008b). Moreover, the presence of 
activated microglia has been found to reduce gap junctional coupling and Cx43 
expression (Faustmann et al., 2003; Rouach et al., 2002b). Also, lipopolysaccharide 
(LPS), which induces inflammatory responses, has been shown to reduce IGJC and 
Cx43 protein level (Bedner et al., 2015; Meme et al., 2006; Retamal et al., 2007). 
 
Malfunction and / or dysregulation of gap junctional communication between 
astrocytes especially in the hippocampus has been associated with diseases and 
pathological conditions like epilepsy (Steinhäuser et al., 2012; Steinhäuser et al., 
2016). Loss of IGJC has been shown in sclerotic hippocampal tissue resected from 
mTLE patients while IGJC was present in non-sclerotic specimens (Bedner et al., 
2015). In the same study a mouse model of epilepsy was used which mimics 
Introduction 
 
 
26 
 
characteristics of human mTLE. In this model reduced IGJC preceded apoptotic 
neuronal death and the onset of chronic seizures and caused impaired K+ clearance 
(Bedner et al., 2015). As a result of pathologically increased neuronal activity, the 
extracellular concentration of K+ ions may increase from 3 mM to 10-12 mM 
(Heinemann and Lux, 1977; Steinhäuser et al., 2012). The extracellular K+ ion 
concentration is mainly balanced and / or controlled by spatial buffering via IGJC 
(Kofuji and Newman, 2004; Steinhäuser et al., 2016). Impaired or reduced IGJC 
results in decreased or no spatial buffering of K+, which can consequently lead to a 
sustained depolarization of the membrane and hyperexcitability that can trigger 
epileptiform activity (Steinhäuser et al., 2016). 
 
In addition to the gap junction mediated communication, Cx43 is also involved in a 
number of other processes. The C-terminal domain of Cx43 contains binding sites 
for different proteins and appears to interact with the cell cycle, transcription control 
and the cytoskeleton (Giepmans, 2004). Beside astrocytic gap junctional 
communication, at least two channel-independent functions of Cx43 are known to 
date. These are the regulation of neurogenesis, neuronal migration and 
differentiation (Elias et al., 2007; Kunze et al., 2009; Prochnow and Dermietzel, 
2008; Wiencken-Barger et al., 2007), and the regulation of the expression of P2Y1 
receptors (Scemes, 2008). Moreover, it was shown that Cx43 regulates the 
transcription of a number of genes in the brains of mice (Iacobas et al., 2007; Spray 
and Iacobas, 2007). 
 
1.5 Temporal lobe epilepsy 
Coordinated activity of neurons is the basis for normal neuronal functioning. 
However, abnormal firing of neurons such as hypersynchronization and hyperactivity 
can result in seizures. Recurrent spontaneous seizures are the typical characteristics 
of epilepsy. Epilepsy has been regarded as a neuronal disorder or a family of 
neuronal disorders, but in 2014 the International League against Epilepsy (ILAE) 
characterized epilepsy as a disease and redefined epilepsy by any of the following 
conditions: “1) At least two seizures occurring more than 24 h apart, 2) one 
unprovoked (or reflex) seizure and a probability of further seizures similar to the 
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general recurrence risk (at least 60%) after two unprovoked seizures, occurring over 
the next 10 years, 3) diagnosis of an epilepsy syndrome” (Fisher et al., 2014). It 
affects about 2 % of the population worldwide (Hesdorffer et al., 2011). Most of the 
focal epileptic seizures in adults originate from the temporal lobe. Hippocampal 
sclerosis (HS) has been observed in most of the cases of TLE (Blumcke, 2009). The 
occurrence of TLE can be sporadic as well as familial (Kobayashi et al., 2001). One 
third of the epileptic patients suffer from intractable epilepsy and do not respond to 
anti-epileptic drugs (AEDs) (Jacobs et al., 2001; Wahab et al., 2010) and TLE 
represent almost even two thirds of cases of intractable epilepsy managed surgically 
(Blair, 2012).  
 
1.6 Febrile seizures 
Retrospective studies have revealed that more than 60 % of TLE patients with 
intractable epilepsy experienced FSs during childhood (Bender et al., 2004; French 
et al., 1993). In follow-up studies it was observed that 2-10 % of children with 
complex FSs developed subsequently  epilepsy (Shinnar, 2003). FSs are the most 
common form of seizures in children. The frequency of the incidences in America 
and Europe is 2-5 %, Japan 8 % and the Marianas Islands around 14 % (Heida and 
Pittman, 2005; Stanhope et al., 1972; Tsuboi and Okada, 1984). The occurrence 
may be sporadic, but familial cases have also been reported. It is likely that both 
genetic and environmental factors might play a role in the development of FSs (Berg 
et al., 1999). FSs occur in infants and young children between the ages of 6 months 
to 5 years, with peak incidence at around 18 months (Hauser, 1994). Simple FSs last 
less than 15 min, do not recur and are generalized without a focal origin. Around 30 
% of FSs are complex, i.e. they have a focal origin, last longer than 15 min and recur 
in 15-20 % of the cases within 24 h (Nelson and Ellenberg, 1976). 
 
However, the role of the FSs in the onset of epilepsy is controversial because both 
prospective and retrospective studies revealed that the simple FSs seem to have no 
measurable effect on the development of epilepsy or other cognitive deficits (Berg 
and Shinnar, 1996; Verity et al., 1985; Verity et al., 1998). However, complex FSs 
can increase 10 times the risk for developing TLE (Pavlidou and Panteliadis, 2013). 
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Also, using magnetic resonance imaging studies it has been revealed that TLE 
patients with a history of FSs have greater probability to develop HS than patients 
without FSs (Sagar and Oxbury, 1987). It was suggested that either FSs cause 
mesial  temporal sclerosis (MTS) and MTS subsequently leads to TLE or FSs cause 
TLE and later MTS results from epileptic seizures (McClelland et al., 2011). But in 
either case FSs seem to be the trigger that initiates a cascade of events which 
subsequently lead to epilepsy (see Fig. 1.3). Experimental FSs (EFSs) generated in 
rats revealed that complex seizures originate in the hippocampus or amygdala (Dube 
et al., 2009). After EFSs interictal activity has been observed in almost 90 % of the 
rats and 35-45 % of the rats became epileptic (Dube et al., 2006; Dube et al., 2010). 
 
There are some genetic factors that might favor the generation of FSs (Berg et al., 
1999). Both in humans and rodents mutations in Na+ channels and GABA receptors 
as well as polymorphism of IL-1β have been associated with FSs and epilepsy 
(Escayg et al., 2000; Harkin et al., 2002; Virta et al., 2002a; Wallace et al., 1998). 
 
1.7 Inflammation 
Inflammation is a response of the body to noxious stimuli. The typical symptoms of 
inflammation are redness, warmth, swelling and pain. Inflammation can be acute and 
/ or chronic. Acute inflammation returns the tissue to its normal state and is then 
resolved. But if the cause of inflammation is persistent than inflammation is 
increased and becomes chronic. Chronic inflammation has been found to be 
associated with many neurodegenerative diseases and epilepsy (Vezzani, 2014). 
 
In the CNS an inflammatory response is elicited by two glial cell types: astrocytes 
and microglia. In response to DAMPs and / or PAMs these cell types are activated 
(Heneka et al., 2014; Town et al., 2005) and respond to maintain homeostasis of the 
tissue (Kreutzberg, 1996). Activated microglia and astrocytes have been observed in 
tissue resected from patients with intractable epilepsy (Beach et al., 1995; Najjar et 
al., 2011) and also have been shown in animal models of epilepsy (Avignone et al., 
2008; Dube et al., 2010; Eyo et al., 2014; Patterson et al., 2015). Both cells types 
undergo pathophysiological, morphological, biochemical changes and release 
Introduction 
 
 
29 
 
inflammatory cytokines such as IL-1β and TNF-α (Dube et al., 2010; Smith et al., 
2012; Vezzani et al., 2008). These cytokines have been found to be associated with 
epilepsy (Vezzani, 2014; Vezzani and Viviani, 2015). Significantly increased levels of 
the inflammatory cytokines IL-1β and TNF-α haven been observed in the serum 
(Choi et al., 2011), plasma (Tutuncuoglu et al., 2001; Virta et al., 2002b) and CSF 
(Haspolat et al., 2002; Tutuncuoglu et al., 2001) of FSs patients  but not in control 
patients with fever without seizures. Similarly, in rats increased protein expression of 
IL-1β has been observed only in animals which developed epilepsy after EFSs 
(Dube et al., 2010). 
 
It has been reported that IL-1β and TNF-α inhibit glutamate reuptake (Hu et al., 
2000; Zou and Crews, 2005) and increase glial glutamate release (Bezzi et al., 
2001), which consequently increases neuronal excitability (Vezzani and Granata, 
2005), reduces seizure threshold and contributes to the generation of EFSs (Dube et 
al., 2005) and promotes epileptogenesis. Inflammatory cytokines have also been 
reported to increase hyperexcitability by their direct effects on neurons. IL1-β 
modulates NMDA receptor activity (Viviani et al., 2003; Yang et al., 2005) which 
results in hyperexcitability (Zhang et al., 2008; Zhang et al., 2010) and promotes 
seizure generation (Balosso et al., 2008). TNF-α increases hyperexcitability by 
enhancing exocytosis of AMPA receptors (Beattie et al., 2002; Stellwagen et al., 
2005) and reducing inhibitory transmission through endocytosis of GABA-A 
receptors (Stellwagen et al., 2005). In addition, as a result of inflammation the BBB is 
disrupted and this compromises the capability of astrocytes to reuptake glutamate 
and buffer K+, ultimately leading to hyperexcitability (Vezzani, 2014). Moreover, a 
positive correlation between BBB leakage and the frequency of spontaneous 
seizures was reported (van Vliet et al., 2007). The suggested cascade of 
inflammatory events leading to epilepsy has been summarized in figure 1.3.  
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Figure 1.3 Pathophysiological cascade of events leading from inflammation to 
epilepsy (Vezzani, 2014). 
 
1.8 TGF-β activated kinase 1 (TAK1) pathway 
TAK1 is a member of the mitogen activated protein kinases (MAPKs) family 
(Yamaguchi et al., 1995). Toll like receptors (TLRs) upon recognition of PAMPs and / 
or DAMPs dimerize and activate downstream signaling pathways. It results in the 
recruitment of myeloid differentiation primary response 88 (MyD88) to the receptor 
via the TLR / IL-1 receptor (TIR) domain. As a consequence MyD88 recruits and 
activates IL-1R-associated kinase-4 (IRAK-4), which in turn phosphorylates and 
activates TNF receptor-associated factor 6 (TRAF6). Upon phosphorylation and 
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activation TRAF6 activates a complex containing TAK1, TAK1-binding protein (TAB) 
-1, and TAB-2/3 (Wang et al., 2001). This activated TAK1 complex mediates the 
activation of a nuclear factor-κB (NF-κB) pathway and the MAPK pathway (Sato et 
al., 2005; Shim et al., 2005; Wang et al., 2001). 
 
The TAK1 complex phosphorylates and activates the IκB kinase (IKK) complex, 
which consists of IKKα, IKKβ, and NEMO (Wang et al., 2001). Upon activation, the 
IKK complex phosporylates IKβ, which than dissociates from NF-κB and is degraded 
via a proteasomal pathway. When NF-κB is released from IKβ, it is activated and 
translocated to the nucleus and results in the activation of gene transcription. In 
addition to NF-κB, TAK1 activates MAPKs including p38, c-jun N-terminal kinase 
(JNK), and extracellular signal-regulated kinase (ERK) that further activates the 
transcription factor AP-1 (Newton and Dixit, 2012). NF-κB and AP-1 promote the 
transcription of pro-inflammatory cytokines like TNFα, IL-6, and IL-1β and 
chemokines (Hayden et al., 2006; Zenz et al., 2008). The activation of TAK1 and its 
downstream signaling molecules is summarized in figure 1.4 (modified from Pathak 
et al., 2012). 
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Figure 1.4 A brief overview of the TAK1 pathway. TAK1 is activated via TLRs in 
response to noxious stimuli, LPS and inflammatory mediators. Upon activation, 
TAK1 can activate MAPKs and NF-κB, which are involved in the transcription and / 
or activation of vital inflammatory, anti-apoptotic and cell signaling molecules. 
Modified from Pathak et al., 2012. 
 
1.9 Lipopolysaccharide 
The most important pro-inflammatory component of gram-negative bacteria is LPS 
(Rietschel et al., 1996). This molecule has an activating effect on cells of the immune 
system including microglia and astrocytes in the brain (Bourdiol et al., 1991; 
Kitchens, 2000). As a result, the activated cells release different inflammatory 
mediators such as IL-1β and TNF-α (Chung and Benveniste, 1990; Szczepanik et 
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al., 1996). TLR4 is responsible for the activation of the signaling cascade by LPS. It 
belongs to the group of TLR receptors that play a central role in innate immunity. 
These receptors recognize in the absence of pathogens also DAMPs (Miller et al., 
2005), that are mostly cytosolic or nuclear proteins that are released as a result of 
the destruction of and / or damage to cells. The TLR family and IL-1 receptors 
belong to the same superfamily of transmembrane receptors that share TIR, a 
common intracellular domain and thus trigger the same signaling cascades (O'Neill 
and Bowie, 2007).  
 
Escherichia coli (E. coli.) containing LPS is among the most important gram-negative 
pathogens. This bacterium is responsible for most of the meningitis diseases in 
infancy. Despite potent antibiotic therapies meningitis caused by gram-negative and 
gram-positive bacteria is correlated with higher complication and mortality rates. Up 
to 70 % of patients with septic meningitis develop septic encephalopathy (Schumann 
et al., 1998). It has been reported that seizures occur in 40 % of patients with 
bacterial meningitis (Anderson, 1993). Experimental results corroborate these 
observations. In animal models it has been demonstrated that LPS reduces the 
threshold for triggering seizures (Galic et al., 2008; Sayyah et al., 2003). 
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2 Aim of the study 
In both retrospective and prospective studies, FSs in children have been suggested 
to increase the risk of developing epilepsy. Also, in animal models it has been shown 
that EFSs increase seizure susceptibility. In previous studies microgliosis, 
astrogliosis and IGJC have been linked with epileptogenesis. The aim of the first part 
of the present study was to investigate EFSs in mice as a consequence of glial 
dysfunction and to explore the probability for epilepsy development in EFS-induced 
animals. 
 
There is increasing evidence, suggesting that inflammation promotes 
epileptogenesis and exacerbates tissue damage. TAK1 has been shown to affect 
inflammation and influence release of inflammatory cytokines. The objective of the 
second part of the present study was to employ cell type-specific TAK1KO mice to 
examine CNS inflammatory responses via microglia activation after status 
epilepticus and to investigate chronic seizure generation in cell type-specific 
TAK1KO mice. 
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3 Materials 
3.1 Chemicals 
In this work, chemicals and solutions from the following manufacturers have been 
used: Applied Biosystems (California, USA), Applichem (Darmstadt, Germany), 
Biostatus (Shepshed, UK), B. Braun (Melsungen, Germany), Carl Roth (Karlsruhe, 
Germany) , Dianova (Hamburg, Germany), Cell Signaling (Danvers, USA), Invitrogen 
(Darmstadt, Germany), Merck (Darmstadt, Germany), Millipore (Darmstadt, 
Germany), Polysciences (Warrington, USA), Promega (Madison, USA) Qiagen 
(Hilden, Germany), Roche (Manheim, Germany), R & D Systems (Germany), Sakura 
Finetek Europe (Zoeterwoude, The Netherlands), Sarstedt (Nümbrecht, Germany), 
Sigma Aldrich (Munich, Germany), Thermo Scientific (Waltham , MA, USA), Vector 
Laboratories (Burlingame, USA), Xencor (Monrovia, USA).  
 
Kits 
GoTaq DNA polymerase (Promega) 
Pierce BCA protein assay Kit (Thermo Fisher Scientific) 
SuperSignal West Dura extended duration substrate (Thermo Fisher Scientific) 
 
3.2 General material 
Borosilicate Glass    Science Products, Hofheim, Germany 
Coverslips, Object slides   Engelbrecht, Edermünde, Germany 
Disposable pipettes    Roth, Karlsruhe, Germany 
Glass pipettes    Brand, Wertheim, Germany 
Gloves     Ansell, Staffordshire, UK 
Instant adhesive    Uhu, Bühl, Germany 
Kimtech     Kimberley Clark 
Needles and Syringes   BD, Franklin Lakes, USA 
Parafilm     Pechiney Plastic Packaging, Chicago, USA 
Plastic Pasteur pipettes   Roth, Karlsruhe, Germany 
Pipetman     Gilson, Middleton, USA 
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PVDF membrane    Millipore, Schwalbach, Germany 
Razor blade     Wilkinson, Bucks, UK 
Reaction tubes, Well plates  Sarstedt, Nümbrecht, Germany 
Surgical instruments   Fine Science Tools, Heidelberg, Germany 
Syringe filters 4 mm    Thermo Fisher Scientific, Waltham, USA 
Tape      Leukoplast, Hamburg, Germany 
Tips, Tubes     Greiner Bio-One, Frickenhausen, Germany 
Venofix     Braun, Melsungen, Germany 
Whatman paper    Whatman International, Maidstone, UK 
 
3.3 Software 
Dataquest A.R.T. 4.00   DataSciences International, St.  Paul, USA 
Gold / Platinum 
GeneTools     Synoptics, Cambridge, UK 
Igor Pro Wave Metrics, Lake Oswego, USA, with 
Macros programmed by Dr. R. Jabs 
ImageJ     NIH, Maryland, USA 
Inkscape     TheInkscape Team 
LAS AF     Leica Microsystems, Wetzlar, Germany 
MC Stimulus II    Multi Channel Systems, Reutlingen, 
Germany 
MetaVue     Molecular Devices, Sunnyvale, USA 
SoftAmx     Pro Molecular Devices, Sunnyvale, USA 
Tida      Heka, Lambrecht, Germany 
SeeTec Office 5    Philippsburg, Germany 
 
3.4 Equipment 
Anti-Vibration Table    Newport Corporation, Irvine, USA 
Bath chamber    Luigs & Neumann, Ratingen, Germany 
Cryostat Cryostat Microm HM560, Thermoscientific, 
Waltham, MA, USA 
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Chemiluminescence chamber Gene Gnome 5 inkl. GeneSys Software 
Syngene, Cambridge, UK 
EEG-Transmitter (telemetric) TA10EA-F20, DataSciences International, 
St. Paul, USA 
Glass pipett Borosilikatglas GB150F-10, Hilgenberg, 
Malsfeld, Germany 
Hair Dryer (6 steps)    Magic, SD-28, 1800 Watt, Germany 
Infra red camera    Optronis VX45, Optronis GmbH, Germany 
Micromanipulator    Micromanipulator 5171, Eppendorf, 
Germany 
Microscope (immunofluorescence) Axiophot Carl Zeiss GmbH, Göttingen, 
Germany With software Metaview, 
Universal Imaging, West Chester, USA 
Microscope (Patch-Clamp)   AxioskopFS1 Zeiss, Oberkochen, Germany 
Patch-Clamp amplifier   EPC 9 and Software Tida 5.x  
HEKA Electronic, Lambrecht / Pfalz 
Germany  
Peristaltic pump ISM 930C Ismatec / Idex, Wertheim / 
Mondfeld, Germany 
Photometer     Molecular Devices, OptiMAX  Sunnyvale, 
USA 
Puller (Pipette puller) P-87 und P-2000 (Sutter Instruments, 
Novato, USA) 
Receiver plate for EEG transmitter RPC-1 DataSciences International, St. Paul, 
USA 
SDS-Page-Systen Mini-PROTEAN® 3 Cell # 165-3301 Bio-
Rad, Hemel Hempstead, UK 
Support for stereotactic injection  TSE Systems GmbH, Bad Homburg, 
Germany 
Transponder for measuring  IPTT-300 BioMedic Data Systems, Seaford, 
body temperature    USA 
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Temperature transponder reader DAS-7007s BioMedic Data Systems, 
Seaford, USA 
Vibratome VT1000S Leica Microsystems, Wetzlar, 
Germany 
Video monitoring system with   SeeTec Axis 221 Indoor Vario 
Infra red cameras 
Voltage source for SDS-PAGE PowerPac™ HC Power Supply  Bio-Rad,  
and WB Hemel Hempstead, UK 
Water bath WB-10 PD-Industriegesellschaft mbH, 
Germany 
Water immersion objective   LUMPlanFL/IR 60 x Olympus, Japan 
WB-System Mini Trans-Blot® # 170-3930 Bio-Rad, 
Hemel Hempstead, UK 
 
3.5 Solutions and buffers 
3.5.1 Solutions for the patch clamp experiment 
Sucrose-preparation solution 
NaCl    87  mM 
KCl    2.5  mM 
NaH2PO4   1.25  mM 
MgCl2    7  mM 
CaCl2    0.5  mM 
NaHCO3   25  mM 
Glucose   25  mM 
Sucrose   75  mM 
pH 7.4 adjusted with carbogen (95 % O2 and 5 % CO2) 
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ACSF 
NaCl    126  mM 
KCl    3  mM 
MgSO4   2  mM 
CaCl2    2  mM 
Glucose   10  mM 
NaH2PO4   1.25  mM 
NaHCO3   26  mM 
and pH 7.4 adjusted with carbogen (95 % O2 and  5 % CO2) 
 
Pipette solution (with biocytin) 
K-Gluconate   130  mM 
MgCl2    1  mM 
Na2-ATP   3  mM 
HEPES   20  mM 
EGTA    10  mM 
Biocytin   0.5 %  w / v 
(N-biotinyl-L-lysin) 
pH 7.2 
 
3.5.2 Solutions and buffers for immunohistochemistry 
Phosphate buffered saline (PBS) 10x 
NaCl    1.5  mM 
Na2HPO4   83  mM 
NaH2PO4   17  mM 
pH 7.4 adjusted with HCl 
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Fixative solution (4% PFA) 
A. dest   800  ml 
Paraformaldehyde  40  g 
- dissolve and add NaOH until the solution is clear  
PBS (10x)   100  ml 
- fill with A. dest to 1000 ml 
pH 7.4 adjusted with NaOH or NaCl 
 
PBS with sodium azide 
NaN3    0.01%  w / v 
dissolved in 1x PBS 
 
Blocking solution 
NGS    10 %  v / v 
Triton X-100   2 %  v / v 
diluted in  1x PBS, pH 7.4 
 
Streptavidin Cy3 solution 
Streptavidin   1:300 
NGS    2 %  v / v 
Triton-X   0.1 %  v / v 
diluted in 1x PBS, pH 7.4 
 
Primary antibody solution 
NGS    5 %  v / v 
Triton-X   0.1 %  v / v 
diluted in 1x PBS, pH 7.4 
 
Secondary antibody solution 
NGS    2 %  v / v 
diluted in 1x PBS, pH 7.4 
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Nuclear staining solutions 
Hoechst   1 %  v / v 
Or 
   Draq5    0.1 %  v / v 
diluted in dH2O 
 
3.5.3 Solutions for the protein analysis (SDS and WB) 
Lysis buffer 
Tris    50  mM 
NaCl    150  mM 
NP-40    0.5 %  v / v 
Na-deoxycholate (10 %) 0.5 %  v / v 
Triton X-100   1 %  v / v 
Fill up to 500 ml with dH2O, pH 7.5 
 
10 x SDS-Page running buffer 
Tris    25  mM 
Glycin    192  mM 
SDS    1 %  w / v 
pH 8.3 (not adjusted, only measured) 
 
10 x Transfer buffer (WB) 
Tris    25  mM 
Glycin    192  mM 
pH 8.3 (not adjusted, only measured) 
 
10 x TBST (Wash buffer) 
Tris    25  mM 
NaCl    150  mM 
Tween 20   0.05 %  v / v 
pH 7.4 (adjusted with HCl or NaOH) 
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Blocking solution (WB) 
Milk powder   5 %  w / v 
Dissolve in wash buffer 
 
Ammoniumpersulfat (APS) (10%) 
APS    0.1  g 
in 1 ml of deionized water 
 
Stacking gel buffer 
Tris    0.5  M 
SDS    0.4 %  w / v 
pH 6.3 
 
Resolving gel buffer 
Tris    1.5  M 
SDS    0.4 %  w / v 
pH 8.8 
 
3.6 Antibodies 
Primary antibodies 
Table 3.1: Overview of the primary antibodies used. 
Antigen Species/Isotype Reaktivity  Dilution Source 
α-Tubulin M /IgG1 Y, H, Ch, R, A, F, B, M IB 1:10.000 Sigma, Cat#T9026 
Cx30 Rb/IgG R, M, C, H IB 1:250  Invitrogen, Cat#71-2200 
Cx43 Rb/IgG M IB 1:5000 Custom made 
GFAP Rb/IgG H, M, R, C, D, S IF 1:400 Dako, Cat# Z0334  
Iba1 Rb/IgG H, M, R IF 1:400 WAKO, Cat# 019-19741 
Iba1 M/IgG H, M, R IF 1:300 Millipore, Cat# MABN92 
NeuN M /IgG1 Av, Ch, Ft, H, M, Po, 
R, Sal 
IF 1:200 Millipore,Cat# MAB377 
abbreviations: H=human, B=bovine, R=rat, M=mouse, Mk=monkey, Ch=chicken, 
GP=guniea pig, Rb=rabbit, Y=yeast, F=fungi, A=amphibian, IF: 
Immunofluorescence; IB: Immunoblot. 
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Secondary antibodies 
Table 3.2: Overview of the secondary antibodies used. 
Antigen Species Dilution in WB Source 
Anti-mouse HRP  sheep anti-mouse IB 1:10.000 GEHealthcare  
Anti-rabbit HRP  donkey anti-rabbit  IB 1:10.000 GEHealthcare  
Streptavidin Cy3  anti-biocytin IF: 1: 300 Sigma Aldrich  
Alexa fluor 594  goat anti-rabbit  IF: 1: 500 Molecular probes 
Alexa fluor 488  goat anti-mouse IF: 1: 500 Molecular probes 
abbreviations: IF: Immunofluorescence; IB: Immunoblot. 
 
3.7 PCR primers 
TAK1fl/fl 
A:    5‘- GGC TTT CAT TGT GGA GGT AAG CTG AGA -3’  
B:    5’- GGA ACC CGT GGA TAA GTG CAC TTG AAT -3’  
 
 
Cx3CR1creER 
Cx3CR1cre Mainz fw: 5’- CCT CTA AGA CTC ACG TGG ACC TG -3’  
Cx3CR1cre Mainz rvwt: 5’- GAC TTC CGA GTT GCG GAG CAC -3’  
Cx3CR1cre Mainz spec 1: 5’- GCC GCC CAC GAC CGG CAA AC -3’ 
 
3.8 Experimental animals 
All the animals were kept in the House for Experimental Therapy (HET) of the 
University of Bonn. Maintenance and handling of all animals used in this study was 
according to the guidelines of European and German animal protection laws. All 
mice were bred and maintained under specific pathogen-free (SPF) conditions. Mice 
were kept under standard housing conditions (12 h / 12 h dark-light cycle, food and 
water ad libitum). All measures were taken to minimize the number of animals used.  
 
3.8.1 Animals used in EFSs experiments  
For hyperthermia (HT) and double hit (DH) experiments C57Bl6J and hGFAP-eGFP 
mice were used. For all experiments only male animals have been used. In all HT 
Materials 
 
 
44 
 
experiments only hGFAP-eGFP mice were used from the FVB strain. In these 
animals, the gene for green fluorescent protein (enhanced green fluorescent protein, 
eGFP) is expressed under the control of the human GFAP (hGFAP) promoter (Nolte 
et al., 2001). Thus, two populations of fluorescent cells are visible in the 
hippocampus: NG2 glial cells usually displayed very faint fluorescence and have 
shorter, less branched processes. In contrast, astrocytes show bright fluorescence, 
are usually larger and show highly branched processes (Matthias et al., 2003).  
 
The astrocytes in which all the electrophysiological experiments have been carried 
out were identified in the following way: first I searched for highly fluorescent cells 
with finely branched processes. These cells were then examined 
electrophysiologically. The cells that showed fluorescence, voltage- and time-
independent current patterns, were used for further experiments. HT and DH 
experiments were carried out with animals aged from 9 to 15 d (p9-p15). All tests 
were performed in the CA1 region of the hippocampus. The focus was on the 
stratum radiatum of the CA1 region. In this region both all staining and coupling 
analysis have been performed. 
 
3.8.2 Animals used in TAK1 experiments 
Cx3cr1CreER:Tak1fl/fl 
To investigate the role of inflammation in epileptogenesis Cx3cr1CreER:Tak1f l/f l and 
Tak1f l/f l animals were used. In these mice TAK1 is conditionally knocked out by Cre-
recombinase fused to a mutant estrogen ligand-binding domain (Cx3cr1CreER) (Yona 
et al., 2013). For the activation of Cre-recombinase and subsequent deletion of 
TAK1 the presence of tamoxifen (TAM) is required. The receptor Cx3cr1 is also 
expressed in peripheral immune cells. But due to the longevity and self-renewal of 
microglia and replacement of peripheral immune cells within short time, TAK1 
remains knocked out only in CNS microglia after TAM administration (Goldmann et 
al., 2013). In these animals TAM (1 mg / mouse) was injected two times a day for 5 d 
consecutively 6 or 7 weeks after birth, and three weeks after TAM injection the 
animals were used for experiments. 
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4 Methods 
4.1 Intraperitoneal injections 
4.1.1 Intraperitoneal injection of LPS  
The concentration of solutions was so adjusted that the final injectable volume of 50 
µl was attained. The substances were dissolved in sterile 0.9 % NaCl solution. The 
dose of LPS administered was 5 mg / kg body weight. 
 
4.1.2 Intraperitoneal injection of TAM 
For intraperitoneal injection TAM was dissolved in sunflower oil in combination with 
ethanol. For making a homogenous solution, the mixture (TAM = 1 mg; sunflower = 
45 µl; ethanol = 5 µl) was subject two times to sonication for 15 min. The dose of 
TAM administered was 1 mg / mice. 
 
4.2 Experimental febrile seizure generation 
4.2.1 Body temperature measurement 
For the measurements of the body temperature disinfected temperature sensitive 
transponders (IPTT-300 BioMedic Data Systems, Seaford, USA) were implanted 1-2 
days before the measurement. These transponders were about 2 x 10 mm in size 
and could easily be introduced under the skin using a special disinfected syringe. 
Thereafter, the animals were observed. The wound healed well and no signs of 
inflammation were evident. In the absence of inflammation, the animals were used 
for further experiments. The use of the transponders allowed the measurement of 
body temperature without taking the animals out of the cage. This has advantages 
over the usual rectal measurements, as the animals can stay at the same ambient 
temperature in the cage. The handling of the animals for rectal measurements can 
also be a source of possible variations, because the animals can be highly stressed 
especially when measurements need to be taken over a longer pe riod, which would 
lead to a rise in the temperature.  
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4.2.2 Hyperthermia induction  
The day the pups were born was considered as P0 (postnatal day 0). Before HT-
treatment, the weight of the animals was at least 5 g, to increase the chances of 
survival and to ensure comparability between test series. The litter size was reduced 
to 5-6 animals for this purpose. Only male animals were used. All experiments were 
performed between 10 am and 4 pm. Due to the young age of the animals, they 
were placed before and after the experiments with their mother and siblings in a 
cage. Before and after HT-treatment the mice were weighed. For HT-treatment, the 
animals were placed at the bottom of a 3 l beaker. The floor of the beaker was 
covered with a two-layer towel cloth. The beaker was placed in a water bath which 
was preheated to 39 °C, to avoid cooling of the animals. In addition, it could also 
derive the surplus heat. 
 
Table 4.1 Behavioral scoring used to characterize EFSs (van Gassen et al., 
2008). 
Stage Behavior Description  
0 Normal  Normal explorative behavior  
1 Hyperactivity Hyperactive behavior, jumping and rearing  
2 Immobility Sudden total immobility (duration 3-10 seconds) 
Ataxia Unsteady, jerk gait 
3 Circling Running in tight circles  
Shaking Whole body shaking  
Clonic seizures Contractions of fore and / or hind limb with reduced consciousness  
4 Tonic-clonic 
convulsions  
Continuous tonic–clonic convulsions with loss of consciousness  
 
The animals were warmed by using a temperature regulated stream of warm air (41 
– 48 °C) coming from a hair dryer. The distance between the hair dryer and the 
animals was approximately 50 cm. With the help of a transformer the heat and speed 
of the air jet could be controlled. The animals were warmed slowly to avoid rapid 
heating and burning of the animals. HT was induced for 36 and 60 min. The duration 
of HT was measured from the time at which the animals showed the behavior 
"sudden immobility". At this stage the first spikes arise in the EEGs (Dube et al., 
2000; Dube et al., 2005). The temperature of the mice was raised to 41.5 °C and 
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kept at 41.5 ± 0.3 °C for 36 or 60 min. The desired temperature of 41.5 °C was 
reached within a few min. The body temperature of the pups was controlled every 
two min. From a measured body temperature of 41.7 °C, the strength and 
temperature of the air jet was reduced until the body temperature had reached the 
value of 41.3 °C. The temperature of 42 °C was not exceeded at any time. During 
the entire duration of HT-treatment behavioral scoring was performed (see Table 
4.1). After 36 or 60 min the protocol was immediately stopped and the body 
temperature of the pups was brought to normal by using water at room temperature. 
The pups were placed back with their mother. For control experiments, untreated 
littermates were used.  
 
4.2.3 Double hit treatment 
In the first experiment, the transponders for temperature measurement were inserted 
in the mice at P11. Either at P13 or P14, LPS (5 mg / kg) was injected 
intraperitoneally (ip). One day after LPS injection (P14 or P15), HT (36 min) was 
induced in the mice using warm air (see section 4.2.2).   
 
In the next experiment, the transponders for temperature measurement were 
inserted in the pups at P11. At P12 LPS (5 mg / kg) was injected ip. HT (36 min) was 
induced on two consecutive days on P14 and P15. From P12 to P16, the cage 
containing pups and mother was kept in water bath to keep them in a warm 
environment, so that they did not lose heat to the environment. The temperature of 
the water bath was maintained at 37 °C.  
 
In the next experiments, the transponders for temperature measurement were 
inserted in the pups at P8. At P9 LPS 5 mg / kg was injected ip. At P11 and P12 HT 
was induced either for 36 min (both days) or 60 min (both days). For these 
experiments two strains of mice, hGFAP-eGFP and C57Bl6J were used. From P9 to 
P13, the cage containing pups and mother was kept in a water bath to keep them in 
a warm environment so that they did not lose heat to the environment. The 
temperature of the water bath was set at 37 °C.  
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4.3 Electrophysiology  
4.3.1 Preparation of acute brain slices  
For the preparation of acute brain slices, mice were anaesthetized by a mixture of 
gases containing 50 % CO2 / 50 % O2 and killed by decapitation. The brain was 
rapidly removed and transferred to ice-cold preparation solution. The cerebellum and 
the frontal third of the brain were cut off. The brain was then glued frontally onto a 
specimen holder with superglue. Subsequently, the specimen holder with the brain 
was fixed in the buffer tray of the vibratome containing ice-cold preparation solution 
constantly gassed with 5 % CO2 / 95 % O2. The brain was cut into 200 µm thin slices 
in coronal orientation. The space around the cutting chamber was filled with a water-
ice mixture. After cutting, the sections were incubated for 20 min in preparation 
solution at 35 °C. The slices were then transferred to gassed (5 % CO2 / 95% O2) 
artificial cerebrospinal fluid (ACSF) (preheated to 35 °C), cooled down to and stored 
at room temperature until further use.  
 
4.3.2 Electrophysiological setup and recording conditions  
The electrophysiological setup used in the present study was composed of the 
following components: An upright microscope (AxioskopFS1 Zeiss, Oberkochen, 
Germany) was mounted on a vibration isolation platform (Newport Corporation, 
Irvine, USA) to ensure stable measurements and placed in a Faraday cage to reduce 
electrical noise. The microscope was equipped with a motorized focus. The 
microscope was further equipped with differential interference contrast (DIC) optics 
to enhance the contrast and improve the recognition of cellular structures in the brain 
slices. To visualize fluorescent proteins expressed by living cells of transgenic mice, 
the setup was equipped with a fluorescence system. The optical signals were 
detected by a CCD-camera and displayed on a monitor. A recording chamber was 
fixed under the objectives of the microscope. The recording chamber was mounted 
on a holder that could be manually moved in x- and y-directions. An electrically-
driven micromanipulator (Micromanipulator 5171, Eppendorf, Germany) was 
available to move the recording pipette. Glass pipettes for patch-clamp recordings 
were pulled with a horizontal puller (P-87 and P-2000, Sutter Instruments, Novato, 
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USA) and had a resistance of 3-4.5 MΩ when filled with pipette solution. Electrical 
signals were recorded by a teflon-coated silver electrode with an uninsulated 
chlorinated tip connected via the preamplifier (head stage) to the patch-clamp 
amplifier (EPC 9, HEKA Electronic, Lambrecht / Pfalz Germany). The reference 
electrode in the recording chamber similarly consisted of a silver/silver chloride 
pellet.  
 
The patch-clamp amplifier operates in two different modes, the voltage-clamp mode 
and the current-clamp mode. In the voltage-clamp mode, the amplifier compares the 
resting potential of a patched cell with the selected holding potential. Whenever a 
difference occurs, current is injected via the pipette electrode to compensate for this 
difference and to keep the cell at the desired holding potential. Consequently, this 
current represents the current flowing over the membrane of the cell and is recorded 
by the amplifier. In the current-clamp mode, the patched cell is at its physiological 
resting potential and no current is injected. Therefore, in this mode physiological 
activity patterns may be recorded as changes in the resting potential.  
 
Signals were filtered at 3 and 10 kHz and sampled at 10 and 30 kHz. The 
appropriate technical devices and software used in the present study are listed in 
section 3.4.  
 
4.3.3 Patch-clamp technique  
Electrophysiological measurements were obtained by applying the patch-clamp 
technique developed by Erwin Neher and Bert Sackmann (Neher and Sakmann, 
1976). Experiments were performed in the conventional whole-cell configuration 
(Edwards et al., 1989; Neher and Sakmann, 1976).  
 
To do so, a brain section was transferred to the recording chamber of the electro-
physiological setup and fixed in place with a u-shaped platinum wire stringed with 
nylon threads. The chamber was constantly perfused (1-2 ml / min) with gassed 
ACSF at room temperature. The recording pipette was filled with pipette solution and 
a constant overpressure was applied via a tubing system. This caused a permanent 
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outflow of pipette solution that prevented plugging of the pipette tip by tissue 
fragments. In the voltage-clamp mode, a depolarizing 10 mV step was applied via 
the pipette electrode to monitor changes in resistance. The pipette was then moved 
under optical control close to the cell membrane. Subsequently, the overpressure 
was released and mild negative pressure applied. This resulted in the formation of 
the cell-attached configuration characterized by a tight connection between cell 
membrane and pipette tip causing a strong increase in resistance ideally reaching 
more than 1 GΩ. During this process the cell was clamped to the holding potential of 
-70 mV (ACSF). Capacitive artifacts caused by the glass pipette were compensated 
at this point. By applying brief pulses of negative pressure the small membrane 
patch under the pipette tip was ruptured resulting in a sudden drop in resistance. In 
this so called whole-cell configuration, currents over the entire cell membrane were 
measured in the voltage-clamp mode. By switching to the current-clamp mode, the 
resting membrane potential was determined. Whole-cell current patterns in response 
to de- and hyperpolarizing voltage steps were offline compensated for capacitive 
artefacts by using IGOR Pro macros custom-written by Dr. Ronald Jabs.  
 
4.3.4 Biocytin visualization  
Functional coupling was analyzed with the biocytin-diffusion method. The biocytin 
molecule is small enough (372.48 Da) to diffuse through gap junctions and its spread 
in the network provides information about the coupling status of the cells. To fill the 
initial cell with biocytin, it was added to the pipette solution in a concentration of 0.5  
% (m / v). The test cells were maintained for 20 min in whole-cell recording to allow 
diffusion of biocytin into the cytosol. During the whole measurement the connection 
between the cell cytosol and the pipette was controlled by recording membrane 
potential, membrane resistance and series resistance every 10 min. Immediately 
after completion of the 20 min, the sections were transferred into a 4 % 
paraformaldehyde (PFA) solution, and incubated at 4 °C overnight to fix biocytin in 
the cells and to prevent further spreading. From this step, unti l the mounting of the 
tissue to the slide, the slices were kept in 24-well plates with each well containing 
250 µl PBS.  
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The next day, the sections were washed three times with PBS (pH 7.4). The washing 
steps were carried out on a shaker at room temperature and lasted 10 min. This was 
followed by an incubation with blocking solution containing 10 % NGS and 1 % Triton 
X-100 in PBS (pH 7.4) for 2 h at room temperature on a shaker. Thereafter, the 
blocking solution was replaced with the antibody solution (Cy3-streptavidin) and 
incubated at 4 °C overnight. The sections were then washed three times and 
incubated for 10 min with Hoechst. After the last washing step, the sections were 
mounted on slides. Attention was paid to the orientation of the slices, so that the  
tissue side stained with biocytin was facing upwards. In general, four slices were 
mounted on a microscope slide. Excess wash solution was removed using filter 
paper. In the middle of the slightly dried sections a drop of mounting medium was 
applied and then covered with a coverslip. After at least 30 min, the sections were 
photographed under the microscope. The program MetaVue was used. Since 
biocytin propagates in all three dimensions in the brain section, several layers were 
taken at a thickness of 1 µm, so that the entire coupling could be detected. For 
counting biocytin-positive cells, the software program ImageJ was used.  
 
4.4 Temporal lobe epilepsy model  
Dr. P. Bedner and Dr. K. Huttmann from our Institute established a new model for 
TLE (Bedner et al., 2015). In this model kainate was injected into the cortex above 
the hippocampus, avoiding mechanical damage to the hippocampus. The new model 
has several advantages compared to the intrahippocampal injection model (Heinrich 
et al., 2006). For instance, mice subjected to intrahippocampal injections do not 
always show spontaneous generalized seizures. Moreover, due to mechanical 
damage produced by the procedure, seizure-induced morphological changes in the 
hippocampus can hardly be investigated.  Briefly, animals were anaesthetized with a 
ketamine / cepetor mixture and injected stereotactically into the right parietal cortex 
(coordinates from bregma point: AP:-1.9 mm and ML:-1.5 mm, DV: 1.8 mm) with 70 
nl kainate (20 mM) using a Hamilton microsyringe. Mice were removed from the 
stereotactic frame and the skin was sutured over the skull. Anesthesia was stopped 
by an ip injection of Antisedan (5 mg / ml Atipamezol hydrochloride) and Ringer in a 
1:4 ratio. Mice were transferred to a clean cage.  
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4.5 Implantation of the EEG electrodes and 
video monitoring 
These experiments were carried out in collaboration with Dr. Peter Bedner and Julia 
Müller. Mice were anesthetized by ip injection of Cepetor (1 mg / ml) and Ketamine 
(10 %) in a ratio of 3:2. To protect the eyes from drying, eye ointment (Bepanthen) 
was applied. Body hair was removed from the scalp and the right abdominal region. 
The shaved areas were disinfected by scrubbing with Cutasept. The mice were fixed 
in a flat skull position in the stereotactic frame holder for stereotactic injection (TSE 
Systems GmbH, Bad Homburg, Germany). A midline skin incision of about 10 mm 
was made in the bregma region and the periosteum was removed to expose the 
skull. On the stereotactic frame a high speed dental drill was mounted. The tip of the 
drill was gently placed on bregma and the stereotactic coordinates were determined. 
The drill was moved 1.9 mm posterior to bregma. Two holes of 0.7 mm diameter 
were drilled bilaterally 1.5 mm from sagittal suture into the skull. In both holes 
stainless steel screws (length 2 mm; thread diameter 0.8 mm; Hummer & Rieß, 
Nürnberg) were inserted. The mouse was removed from the stereotactic frame. For 
implantation of the telemetric transmitter (TA10EA-F20, Data Sciences International, 
St. Paul, USA), a 15 mm long skin incision was made in the right abdominal region, 
and a subcutaneous skin pouch was created by blunt dissection underneath the skin. 
A tunnel for the leads was made in the same manner by moving cranially until 
reaching the mid-sagittal incision. The disinfected telemetric transmitter was placed 
into the previously prepared skin pouch and the skin was closed with wound clips. 
The two monopolar leads were subcutaneously pulled cranially and connected to the 
screws. The connected leads were then covered with dental cement (Paladur, 
Heraeus Kulzer GmbH) and the skin was sutured. Anesthesia was stopped by ip 
injection of Antisedan (5 mg / ml Atipamezol hydrochloride) and Ringer in a 1:4 ratio.  
Mice were injected with Carprofen (4 mg / kg, ip.) for 3 d to reduce pain and 0.25 % 
Enrofloxacin was administrated via drinking water to reduce the risk of infection. 
Mice were transferred to a clean cage and placed on a receiver plate (RPC-1; Data 
Sciences International). The plates received the signals from the telemetric 
transmitter and sent it to a computer with Dataquest ART 4:00 Gold / Platinum 
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software (DataSciences International). At the same time, the behavior of the animals 
was recorded using a Video Surveillance System (SeeTec, Phillipsburg, Germany) 
equipped with two infrared cameras (Axis 221 Indoor Vario).  
 
4.6 Immunohistochemistry 
4.6.1 Cardiac perfusion and fixation  
To obtain well preserved brain sections for immunohistochemistry (IHC) transcardial 
perfusion was carried out. First, mice were anesthetized with ip injection of Cepetor-
KH (1 mg / ml) and Ketamine (10 %) in a ratio of 3:2. With fine scissors the chest 
was opened and the pericardium exposed. Subsequently, a 25-G cannula was 
inserted into the left ventricle. The right atrium was cut open with scissors so that the 
blood can flow out. During the whole perfusion process, 30 ml PBS (pH 7.4) was 
slowly injected to remove blood, followed by further pumping of 30 ml 4 % PFA for 
fixation. Successful perfusion was indicated by the animal becoming rigid. Later, the 
skull was opened and the brain isolated, then fixed again in 4 % PFA overnight at 4 
°C. The next day the brain was transferred to 30 % sucrose solution in PBS and was 
kept at 4 °C for at least 3 days. 
 
4.6.2 Cryosection preparation 
After 3 days in sucrose solution the brain was embedded in Tissue-Tek (Sakura 
Finetek, Europe) and frozen at -80 °C. The sections for IHC were cut on a cryostat 
(Microm HM560, Thermoscientific, Waltham, MA, USA) and were 40 µm thick. 
Storing of the sections was carried out in PBS (pH 7.4) in 24-well plates and 0.01 % 
sodium azide as a preservative in order to ensure a longer life.  
 
4.6.3 Immunofluorescence staining  
All stainings were performed on 40 µm thick cryosections. The sections were 
washed 3 times in PBS (pH 7.4) at room temperature. Subsequently, they were 
incubated for permeabilization in blocking solution for 1 h at room temperature. The 
blocking solution contained 10 % NGS and 1 % Triton X-100 in PBS (pH 7.4). 
Thereafter, the sections were incubated with respective primary antibodies (see 
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Table 3.1) in PBS containing 5 % NGS and 0.1 % Triton X-100 overnight at 4 °C. 
Later, the sections were washed three times with PBS at room temperature. The 
sections were incubated with respective secondary antibody (see Table 3.2) in PBS 
containing 2 % NGS and then washed three times with PBS at room temperature. 
Next, nuclear staining was performed with Hoechst 1:100 in PBS. Again, the 
sections were washed three times in PBS. Thereafter, the sections were mounted on 
slides and observed under the microscope. 
 
For p-TAK1 x Iba1 staining, mouse monoclonal anti-Iba1 antibody (see Table 3.1) 
was used and the sections were incubated with L. A. B. medium for 15 min at room 
temperature. After this, the sections were washed three times in PBS (pH 7.4) at 
room temperature followed by incubation for permeabilization. For nuclear staining 
Draq5 was used. Furthermore, the sections were incubated with primary antibodies 
for three days. The rest of the protocol was similar as already described.  
 
4.6.4 Fluoro-Jade C staining 
For fluoro-jade C / DAPI double staining, Biosensis Ready-to-Dilute (RTD) TM kit 
(Cat# TR-100-FJ, Biosensis, Thebarton, Australia) was used following the 
manufacturer instructions. First, 40 µm thick brain sections were mounted on 
superfrost Ultraplus slides (Thermo Scientific, Braunschweig, Germany) and dried at 
50 °C for 30 min on a slide warmer. For 5 min, slides were incubated in a coplin jar 
containing one part sodium hydroxide mixed with 9 parts of 70 % ethanol at room 
temperature. After this the slides were washed with 70 % ethanol for two min at room 
temperature. Then the slides were rinsed with distilled water for two min at room 
temperature. The slides were transferred into a new coplin jar containing a mixture of 
one part KMNO4 in 9 part water and incubated for 10 min. After this the slides were 
rinsed in distilled water for two min. The slides were transferred into a new coplin jar 
containing one part Fluoro-Jade C, one part DAPI and 8 parts water, and incubated 
for 10 min at room temperature. The slides were rinsed three times in distilled water 
for one min at room temperature.  The slides were air dried on a slide warmer at 50 
°C for 5 min. For clearing, the slides were immersed in xylene for two min at room 
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temperature. The slides were coverslipped using DPX mountant (Sigma) and images 
were taken using a confocal microscope (Leica SP8). 
 
Slices from mice intracortically injected with kainate (see section 4.4) were used as 
positive controls. 
 
4.6.5 Micrographs  
Immunofluorescence stainings were analyzed by microscopy. Images were acquired 
at 1 µm intervals using either a fluorescence microscope (Axiophot employing 
MetaVue software) or a confocal (LSMs Leica SP8). Fluorescence image resolution 
was 2084 x 2084 pixels and LSM images were acquired at 1024 x 1024 pixels. 
Tracer filled networks were imaged employing a 20 x objective. For co-localization 
studies confocal images were acquired. Cell type analysis in different brain areas 
was performed on image stacks of 290.62 x 290.62 x 15-20 µm3 volumes if not 
stated otherwise. The images obtained were analyzed using Fiji software and figures 
were edited using ImageJ. 
 
4.7 Protein chemistry 
4.7.1 Total protein extraction from tissue  
Hippocampi of mice were used for protein extraction. All steps were performed on 
ice. An inverted petri dish covered with filter paper was used as a base. Mice were 
sacrificed by cervical dislocation. The brain was immediately isolated and it was 
dissected out. It was washed with ice-cold PBS to remove residual blood. The 
cerebellum was removed and the brain was separated into two hemispheres. Then, 
the olfactory bulbs were cut off with part of frontal cortex and the rest of the brain 
was put on a coronal plane. Using two small spatula the cortex was then carefully 
removed. With the aid of the blunt side of the spatula , hippocampi were carefully 
isolated from the midbrain, collected in an Eppendorf tube and immediately frozen in 
liquid nitrogen. The tissue was stored at -80 °C or subsequently prepared in a 
modified RNA Immuno- Precipitation Assay (RIPA) lysis buffer (50 mM Tris, 150 mM 
NaCl, 0.5 % Nonidet P40, 0.5 % Na-DOC, 1 % Triton X-100, 0.5 % SDS) 
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supplemented with halt protease and a phosphatase inhibitor cocktail (Thermo 
Scientific). Then, the tissue was homogenized with a plastic pestle in a 1.5 ml tube in 
about 300 µl lysis buffer and disrupted with a pre-chilled 27 gauge needle (Braun, 
Melsungen; Germany) and supersonic salt (until homogeneous). After incubation on 
ice for ~ 30 min, supernatants were collected by centrifugation for 30 min at 13,000 x 
rcf at 4 °C. Total protein content was assayed with the BCA (Pierce, Bonn, Germany) 
method using 5 µl supernatant of each sample. To avoid frequent frosting and 
defrosting of the samples, aliquots were prepared with 70 µl volume. The samples 
were stored at -80 °C.  
 
4.7.2 SDS-page and Western blot  
For immunoblotting studies, 40 µg total protein per sample was analyzed in each 
sample. The lysates were treated with the "Laemmli" sample buffer (Rotiload 4x) and 
denatured by heating for 10 min at 65 °C. After that samples were spin briefly and 
separated with 12 % SDS resolving gel for 60 - 90 min at 80-180 V in denaturing 
conditions. To estimate protein size, pre-stained protein ladder (PageRuler, Thermo 
Scientific) was loaded along with the samples. Since the markers used were 
conjugated with a dye to directly observe movement of the proteins in the gel, there 
was small run imprecision in individual bands. Polyvinylidene fluoride (PVDF) 
membranes (Millipore, Darmstadt, Deutschland) were used for electroblotting of 
separated proteins for 2 h at 500 mA running condition. Subsequently, the 
membranes were blocked with 5 % milk powder in TBST (pH 7.4) containing 0.05 % 
Tween-20 and incubated overnight at 4 °C on a rotator with primary antibodies: 
rabbit polyclonal anti-Cx43 (1:5000, custom made), rabbit polyclonal anti-Cx30 (1: 
250, Invitrogen, Darmstadt, Germany), mouse monoclonal anti-α-tubulin (1:10,000, 
Sigma, Steinheim, Germany). Visualization was performed with HRP-conjugated 
secondary antibodies. The membranes were first washed three times for 10 min with 
TBST to remove unbound primary antibody. This was followed by incubation with the 
secondary antibodies for 1 h at room temperature. Secondary antibodies used: goat-
anti-mouse HRP conjugate (1:10,000, GE Healthcare, Little Chalfont 
Buckinghamshire, UK) goat-anti-rabbit HRP conjugate (1:10,000, GE Healthcare). All 
antibodies, including secondary antibodies, were diluted in 5 % milk powder in TBST 
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(pH 7.4) containing 0.05 % Tween-20. For visualization of HRP, the Super signal 
West Dura substrate (Pierce) was used and chemiluminescence was detected with 
the Gene Gnome digital documentation system (Synoptics, Cambridge, UK). Equal 
loading of the lanes was confirmed by α-tubulin staining of the same membrane. For 
inactivation of secondary antibodies, membranes were incubated in 100 mM sodium 
azide in 5 % milk overnight at 4 °C. Quantification was performed using the program 
ImageJ software. Quantification and analysis of phosphorylation states of Cx43 were 
performed by PhD student Tushar Deshpande. The chemiluminescent intensity of 
each band was measured and normalized against the corresponding α-tubulin band. 
Because all samples were exposed to identical conditions (substrate and time), a 
relative comparison of protein expression between different samples was possible.  
 
4.8 Data analysis  
All error bars in the bar graphs represent standard deviation (SD). For statistical 
analysis the following methods have been applied: when comparing two groups 
Student's T-test was used; when comparing more than two groups, two-sided 
variance analysis (ANOVA) followed by Tukey's test has been used. In all cases, a 
significance level of 5 % was applied (p < 0.05).  Exception to this rule is explicitly 
stated in the text and in figure captions. 
 
4.9 Genotyping 
4.9.1 DNA extraction 
Genomic DNA was obtained from small tail tips of 3 weeks old mice. Samples were 
incubated in 300 µl Laird buffer supplemented with Proteinase K (20 U / ml) at 55 °C 
overnight in a water bath. The next day lysates were vortexed and centrifuged at 
13,000 rcf for 10 min at room temperature. The supernatant was transferred to a new 
tube and the DNA was precipitated by adding 300 µl isopropanol and gently mixing 
the solutions. After another centrifugation step at 13,000 rcf for 10 min at room 
temperature the supernatant was discarded. The DNA pellet was washed in 70 % 
ethanol (500 µl) and centrifuged again at 13,000 rcf for 10 min at room temperature. 
The supernatant was discarded and the DNA pellet was air dried for 1 h and 
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dissolved in 50 µl of ddH2O. Genomic DNA was subsequently used for routine 
genotype analysis with different primers. 
 
4.9.2 Polymerase chain reaction 
DNA samples were amplified by polymerase chain reaction (PCR). The method 
relies on several thermal cycling reactions for melting, primer annealing and 
subsequent replication of the target DNA. Primers were designed to bind at the 3'-
end of the sense and antisense strands of the DNA sequence to be amplified. 
Employing a heat-stable Taq polymerase the DNA strands were amplified by 
elongation of the primers in 5'-3' direction. This enzyme was originally isolated from 
the bacterium Thermus aquaticus. The following Tables 4.2, 4.3, 4.4 and 4.5 show 
the PCR mix and the applied PCR protocols for genotyping animals of the 
TAK1f l/f l:Cx3cr1CreER mouse line; the presence of a floxed TAK1 and the presence of 
a cre-recombinase allele was detected by PCR. After the completetion of the PCR, 
the samples were kept at 8 °C (step 6 in table 4.3 and table 4.5) untill taken out from 
the PCR machine. The total volume of the PCR mix was 24 µl and 1-2 µl DNA were 
added. 
 
Table 4.2 TAK1fl/fl PCR protocol 
PCR mix Volume [µl] 
ddH2O 14.3 
PCR buffer 5x  5 
MgCl2 (25 mM) 1 
Primer A  (10 pmol/µl) 1.25 
Primer B  (10 pmol/µl) 1.25 
dNTP (each 10 mM) 1 
Taq polymerase 0.2 
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Table 4.3 TAK1fl/fl PCR program 
Step Temp. [°C] Time [min] Cycles 
1 94 5 1 
2 94 0:45 2-4 35x 
3 67 0:45  
4 72 0:45  
5 72 7 1 
6 8 ∞ 1 
 
 
Table 4.4 Cx3cr1CreER PCR protocol 
PCR mix Volume [µl] 
ddH2O 13.05 
PCR buffer 5x  5 
MgCl2 (25 mM) 1 
Primer Cx3CR1
cre
 Mainz fw (10 pmol/µl) 1.25 
Primer Cx3CR1
cre
 Mainz rvwt (10 pmol/µl) 1.25 
Primer Cx3CR1
cre
 Mainz spec 1 (10 pmol/µl) 1.25 
dNTP (each 10 mM) 1 
Taq polymerase 0.2 
    
 
Table 4.5 Cx3cr1CreER PCR program 
Step Temp. [°C] Time [min] Cycles 
1 94 5 1 
2 94 0:45 2-4 35x 
3 62 0:45  
4 72 0:45  
5 72 7 1 
6 8 ∞ 1 
 
4.9.3 Agarose gel electrophoresis 
The PCR products were separated by agarose gel electrophoresis. The DNA 
samples were separated by their size and charge, therefore a 1.5 % agarose gel 
containing 0.8 µg / ml ethidium bromide was prepared. Due to the negatively 
charged phosphate groups, DNA moved to the anode and the migration velocity was 
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proportional to their molecular mass. Ethidium bromide was added to visualize the 
DNA under ultraviolet light; it intercalates double stranded DNA. Gel electrophoresis 
was performed at 110 V for 45 – 60 min. At the same time, a 100 bp DNA ladder was 
run along with the samples to estimate the molecular size of the amplified DNA 
fragments. All genotyping experiments were performed by PD Dr. Gerald Seifert. 
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5 Results 
5.1 Consequences of EFSs on the hippocampal 
astrocytic network 
5.1.1 EFSs generation 
Retrospective studies have shown that 20-60 % of the patients suffering from 
intractable TLE had a childhood experience of FSs (French et al., 1993; Hamati-
Haddad and bou-Khalil, 1998). Also, in some follow up studies it has been observed 
that FSs during early childhood increase the risk of developing TLE in later life 
(Annegers et al., 1987; Nelson and Ellenberg, 1976). It has been shown that this risk 
varies among individuals and can be dependent on various factors like the duration 
of FSs, its reoccurrence and age of the patient at the time of the first FS (McClelland 
et al., 2011). It has been revealed that the risk of developing TLE is lower for simple 
FSs and higher for complex FSs. Between 2 and 6 % of children suffer from FSs 
during early childhood (Nelson and Ellenberg, 1976; Shinnar and Glauser, 2002). 
 
To investigate the effects of FSs in infants, EFSs were induced in hGFAP-eGFP and 
C57Bl6J mice under different conditions (Table 5.1). The decrease in body weight 
was less than 5 % in all EFS experiments (Table 5.1). The duration of EFS 
generation was measured from the time point when the animals showed the first 
sudden immobility phase (Table 5.1). It has been shown that the first sudden 
immobility phase indicates the onset of seizure (see section 4.2.2) (Dube et al., 
2000; Dube et al., 2005). After completion of the protocol for EFSs generation the 
mice were partly submerged in water of room temperature to quickly normalize their 
body temperature and were subsequently returned to their mother. The summary of 
important parameters recorded during the EFS experiments is given in table 5.1. 
During HT-treatment for EFSs generation the behavior was recorded and scaled 
(see Table 4.1) as previously described by van Gassen et al. (2008). 
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Table 5.1 Summary of different parameters used for EFSs generation 
 LPS 
day 
Episode HT 
day 
Body 
weight 
loss (%) 
Interval till 
first sudden 
immobility 
Average body temperature   duration 
of HT  
n 
 at first sudden 
immobility 
during HT 
treatment 
FVB-hGFAP-eGFP 
HT   P14 
or 
P15 
3.3 ± 1 6 ± 2 min 39.4 ± 0.2 41.2 ± 0.6 36 min 21 
DH-I P13 
or 
P14 
 P14 
or 
P15 
3.7 ± 
0.7  
5 ± 2 min 40.7 ± 0.4 41.5 ± 0.3 36 min 21 
DH-II P12 1
st
 P14 3.2 ± 
0.7  
7 ± 4 min 39.7 ± 0.8 41.3 ± 0.6 36 min 10 
2
nd
 P15 3.6 ± 
0.8  
7 ± 2 min 40.2 ± 0.6 41.4 ± 0.4 
DH-III P09 1
st
 P11 3 .3 ± 1 5 ± 1 min 39.7 ± 0.2 41.3 ± 0.4 36 min 9 
2
nd
 P12 4.0 ± 
1.6  
5 ± 2 min 39.9 ± 0.4 41.4 ± 0.4 
DH-IV P09 1
st
 P11 3 .0 ± 1 5 ± 2 min 39.4 ± 0.2 41.3 ± 0.4 60 min 18 
2
nd
 P12 3.7 ± 1 5 ± 1 min 39.5 ± 0.2 41.3 ± 0.4 
C57Bl6J 
DH-V P09 1
st
 P11 3.1 ± 1 7 ± 1 min 40.3 ± 0.2 41.4 ± 0.3 36 min 8 
2
nd
 P12 3.1 ± 1 6 ± 2 min 40.4 ± 0.2 41.5 ± 0.2 
DH-VI P09 1
st
 P11 3.4 ± 1 9 ± 1 min 40.1 ± 0.5 41.4 ± 0.3 60 min 6 
2
nd
 P12 3.7 ± 
0.7 
7 ± 2 min 40.4 ± 0.3 41.4 ± 0.3 
abbreviations: HT = hyperthermia, DH = double hit experiment 
 
In the HT experiments (Table 5.1), animals showed hyperactivity including jumping, 
rearing, chewing, swallowing and grooming. Some animals also showed ataxia and 
falling on side or back. Typical behavior during the last 10 min of the protocol was 
lying on one side. Seldom clonic contraction of fore and / or hind limbs was 
observed. Very few pups showed circling or running in tight circles but all showed 
face automatisms (chewing, swallowing and grooming). 
 
During HT induction, the temperature of the body and brain increases, which causes 
FSs. As the animals are kept in SPF conditions, it is unlikely that they experience 
any infection before HT-treatment and FSs onset. However, in most human cases, 
children first get an infection which leads to an increase in body temperature , and in 
some cases causes FSs (Chiu et al., 2001). It has been reported that a handsome 
percentage of TLE patients experienced FSs during early childhood (Cendes et al., 
1993). Therefore, to mimic early childhood FSs generation in humans, LPS was 
injected ip before HT-treatment. Also, it has been shown that administration of LPS 
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in pups in early age increases seizure susceptibility (Galic et al., 2008). Therefore, in 
DH experiments a single dose of LPS (5 mg / kg) was injected prior to HT-treatment 
(see Table 5.1). 
 
In double hit I (DH-I) experiments, LPS was injected one day before HT treatment 
(Table 5.1). The animals showed hyperactivity including jumping, chewing, 
swallowing, ataxia, lying on side or back. Running in tight circles, shaking and falling 
on side or back were also observed in some animals. During the last half of the 
protocol animals showed clonic contractions of fore and / or hind limbs as well as 
face automatisms. But when back in the cage with the mother, the animals became 
immobile within 5 min and their body temperature fell down. Around 25 % of the 
animals could not increase their body temperature and died of freezing. The rest of 
the animals became mobile in 15-20 min. 
 
After LPS administration, the animals became much more sensitive to HT-treatment, 
and almost 25 % of the animals died within one day after HT-treatment. Considering 
the acute inflammatory response in some animals being responsible for the disability 
to regulate body temperature, the LPS administration day and the duration between 
LPS administration and HT-treatment was changed. The cages of the animals were 
kept in a water bath which had a stable temperature of 37 °C to avoid heat loss from 
the experimental animals. The cage of the animals was removed from the water bath 
one day after HT-treatment. This avoided sudden heat loss or freezing of animals 
after LPS administration and subsequently mortality rate decreased to less than 5 % 
after HT-treatment. As it has been reported that recurrence of seizures within 24 h 
(i.e. complex FSs) increases the risk for developing TLE (Pavlidou and Panteliadis, 
2013), a second episode of HT-treatment was given within 24 h. In double hit II (DH-
II) experiments LPS was injected on P12, and HT was induced on two consecutive 
days (P14 and P15). These animals showed less hyperactivity (jumping) than the 
animals in the previous experiment. These animals showed ataxia and lying on side 
or back. Face automatisms accompanied with clonic contractions were observed but 
falling on side or back was missing. Very few animals showed running in tight circles 
but shaking was observed. When placed back with the mother, after 5 min animals 
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became immobile and remained immobile for about 30-35 min. During this time the 
animals continued to show face automatisms and clonic contractions. Due to the 
stable temperature of the water bath which avoided heat loss of the animals, fall in 
body temperature of the animals after HT-treatment was not observed. 
 
The mammalian brain keeps continue maturation after birth and passes through 
different stages (Stiles and Jernigan, 2010). Also the inflammatory response can 
change with age. Therefore, the postnatal day for LPS administration and HT-
treatment was changed to investigate the effect of age on the consequences of DH 
treatment. In the double hit III (DH-III) experiment, LPS (5 mg / kg) was administered 
on P9 and HT-treatment was performed on P11 and P12 (Table 5.1). The animals 
showed ataxia and sudden immobility throughout the protocol. Falling on side or 
back was also observed. Some pups displayed clonic contractions of fore and / or 
hind limbs combined with face automatisms. When put back with their mother after 
stopping the protocol, animals continued to show face automatisms and clonic 
contractions of fore and / or hind limbs for 10-15 min. 
 
As the total duration of FSs can also have effects on epileptogenesis, the duration of 
HT-treatment was increased to 60 min in the double hit IV (DH-IV) experiment (Table 
5.1). During the first 10-15 min after the first sudden immobility phase, these pups 
showed hyperactivity, but later on hyperactivity was decreased. The pups did not 
show circling or running in tight circles, but falling on side or back was observed. The 
pups exhibited whole body shaking, contractions of fore and / or hind limbs and face 
automatisms. In the last 20-25 min the pups started to show tonic clonic contractions 
of fore and hind limbs combined with loss of consciousness for short periods of time 
(10 – 20 s), the duration of which progressively increased to more than 120 s 
towards the end of the protocol. When back with the mother, the pups continued to 
have continuous tonic clonic contractions of fore and hind limb with loss of 
consciousness for 15-20 min. 
 
Using HT-treatment it has been shown that different strains of mice show different 
seizure susceptibility during EFS generation (van Gassen et al., 2008). To 
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investigate whether seizure susceptibility changes or remains the same in a different 
strain of mice during FSs generation caused by HT-treatment in combination with 
LPS administration, C57Bl6J animals were used. 
 
In the double hit V (DH-V) experiment, LPS (5 mg / kg) was injected on P9 and HT 
was induced on two consecutive days (P11 and P12) for 36 min (Table 5.1). The 
animals showed hyperactivity for a short period of time after a first sudden immobility 
phase. These pups exhibited ataxia and immobility throughout the protocol. They 
also presented whole body shaking, circling, and clonic contractions of fore and / or 
hind limbs. When back with the mother, for 10-15 min the pups showed episodes of 
continuous tonic–clonic convulsions with loss of consciousness. 
 
The duration of HT-treatment was increased to 60 min in the double hit VI (DH-VI) 
experiment. The pups showed hyperactivity in the first few minutes after a first 
sudden immobility phase. They displayed sudden immobility and ataxia throughout 
the protocol. Whole body shaking and running in circles was also present. Clonic 
contractions were observed 10 min after first sudden immobility unti l 40 min. After 
this the animals started to show tonic-clonic convulsions (30-90 s long), which were 
succeeded by status epilepticus in the last 8-10 minutes. When back with the mother 
the pups continued showing tonic-clonic convulsions for about 45 - 60 min. 
 
5.1.2 Neuronal degeneration and neuronal density 
In adult animal models of hippocampal epilepsy, neuronal cell death in the CA1 and 
CA3 pyramidal cell layers in addition to the hilus have been shown, which is similar 
to the situation in human TLE (Freund et al., 1992; Nadler, 1981). To investigate 
whether HT-induced seizures also induce neurodegeneration, Fluoro Jade C 
stainings were performed 6 h and 5 d after HT-treatment. For positive control 
sections from mice perfused 5 d after kainate-induced status epilepticus were used. 
Here, massive neuronal degeneration was observed (Fig. 5.1A). However, no 
neuronal death was found in pups 6 h (see Fig. 5.1B) and 5 d (see Fig. 5.1C) after 
HT-treatment. 
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Figure 5.1 Fluoro Jade C staining for neuronal degeneration. Fluoro-Jade C 
staining did not indicate EFSs-induced neuronal degeneration. (A) Fluoro-Jade C 
(green) / Dapi (blue) signal in slices from animals intracortically injected with kainate, 
which served as a positive control. Five days after kainate-induced status 
epilepticus, many pyramidal neurons displayed green fluorescence. (B and C) 
Representative images showing Fluoro-Jade C / DAPI double staining in the 
hippocampal CA1 subfield 6 h and 5 d (respectively) after EFSs (HT). Note lack of 
Fluoro-Jade C immunoreactivity. s.o. = stratum oriens; s.p. = stratum pyramidale; s.r. 
= stratum radiatum. Scale bar = 50 µm. 
 
The density of pyramidal neurons in CA1 region of hippocampus was investigated by 
NeuN staining. Neuronal staining for untreated controls and HT-treated pups is 
shown in figure 5.2A. The number of NeuN positive cells was counted in a volume of 
290.62 x 290.62 x 15 µm3 within the CA1 stratum pyramidale of the hippocampus. 
There was no difference in the number of NeuN positive cells in hippocampi of EFS 
(HT) mice and untreated control (UC) littermates (number of Neun positive cells: UC 
= 277956 ± 34141 vs. HT = 278896 ± 26152, n = 9 slices from 3 animals were used 
for each condition, p = 0.9, T-test; see Fig. 5.2B). 
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Figure 5.2 Immunohistochemical analysis of neuronal density in hippocampal 
sections from immature mice subjected to EFSs. Slices were prepared from 
brains obtained from mice perfused 5 d after EFSs and untreated control littermates. 
(A) NeuN (red) / Hoechst (blue) double staining revealed no reduction in the 
numbers of pyramidal neurons (B). s.o. = stratum oriens; s.p. = stratum pyramidale; 
s.r. = stratum radiatum. Scale bar = 50 µm. 
 
5.1.3 Microglia activation 
To investigate whether EFSs cause inflammation, microglia activation was examined 
5 d after HT-treatment through Iba1 antibody immunostaining (see Fig. 5.3). Altered 
microglia morphology (hypertrophic cell bodies and processes) was observed in the 
hippocampi of HT-treated mice as compared to room temperature-treated and 
untreated control littermates (Fig. 5.3A). Iba1 immunoreactivity was significantly 
increased in hippocampi of HT-treated mice compared to hippocampi of room 
temperature-treated and untreated control littermates (area occupied by Iba1: HT = 
2.8 ± 0.2 % vs. room temperature = 0.8 ± 0.5 % and UC = 1.1 ± 0.6 %, n = 9 slices 
from 3 animals for each condition, p < 0.05, post hoc Tukey HSD; Fig. 5.3B). The 
number of Iba1-positive cells observed in a volume of 290.62 x 290.62 x 15 µm3 was 
also significantly higher in HT-treated mice when compared with room temperature-
treated and untreated control littermates (number of Iba1-positive cells: HT = 39729 
± 2772 vs. room temperature = 29731 ± 1205 and UC = 27889 ± 3893, n = 9 slices 
from 3 animals for each condition, p < 0.05, post hoc Tukey HSD; Fig. 5.3C). 
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Figure 5.3 Immunohistochemical analysis of Iba1-positive microglia in 
hippocampal sections from immature mice subjected to EFSs. Slices were 
prepared from brains of animals perfused 5 d after HT-treatment, room temperature-
treatment and untreated control littermates. Microglia activation could be detected by 
Iba1 (green) / Hoechst (blue) double staining (A). The area occupied by Iba1-positive 
cells was significantly higher in HT-treated mice than in room temerature-treated and 
untreated control littermates (B). The number of Iba1-positive cells was significantly 
higher in HT-treated mice as compared to room temperature-treated and untreated 
control littermates (C). s.o. = stratum oriens; s.p. = stratum pyramidale; s.r. = stratum 
radiatum. Scale bar = 50 µm. Asterisk indicates p < 0.05 (post hoc Tukey HSD). 
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5.1.4 Reactive astrogliosis 
Astrocytes play an important role in maintaining ion and neurotransmitter 
homeostasis in the healthy brain (Volterra and Meldolesi, 2005). In addition to their 
response in the form of potentiating and restricting CNS inflammation (Sofroniew, 
2015), astrocytes actively contribute to neural metabolism, synaptic plasticity and 
neuroprotection (Chung et al., 2015; Colangelo et al., 2014). In response to toxins, 
traumatic insults or inflammation the morphology, biochemistry and physiology of 
astrocytes change and their density increases. These changes in response to CNS 
insults are collectively termed as “reactive astrogliosis” (Sofroniew and Vinters, 
2010). 
 
To investigate reactive astrogliosis, 40 µm thick sections obtained from HT-treated 
and untreated control mice were stained with GFAP antibody. Under both conditions 
GFAP positive cells displayed similar gross morphology and density (Fig. 5.4A). The 
area occupied by GFAP in the stratum radiatum of the hippocampal CA1 region was 
quantified using image J. There was no difference in the area occupied by GFAP 
between HT-treated mice and untreated control littermates (percent area occupied 
by GFAP: UC = 0.65 ± 0.09 % vs. HT = 0.61 ± 0.14 %, n = 9 slices from 3 animals 
were used for each condition, p = 0.7, T- test; Fig. 4B). 
 
 
Figure 5.4 Immunohistochemical analysis of GFAP activation in hippocampal 
sections from immature mice subjected to EFSs. Slices were prepared from 
brains isolated from animals perfused 5 d after HT-treatment and from untreated 
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control littermates. (A) GFAP (green) / Hoechst (blue) double staining revealed no 
astrogliosis (B). s.o. = stratum oriens; s.p. = stratum pyramidale; s.r. = stratum 
radiatum. Scale bar = 50 µm. 
 
5.1.5 EFSs induce a reduction in IGJC 
Previously it has been shown that kainate-induced status epilepticus triggers a rapid 
reduction of astrocyte gap junctional coupling, a glial dysfunction that is considered 
to be a major event in epileptogenesis (Bedner et al., 2015). To investigate the 
influence of EFSs on astrocyte coupling, astrocyte gap junctional networks were 
studied in acute brain slices obtained from hGFAP-eGFP mice 5 d after EFSs 
generation under different conditions and untreated control littermates (see Table 5.1 
and Table 5.2). The extent of astrocyte coupling was estimated by evaluating 
intercellular diffusion of biocytin to neighboring astrocytes from an individual 
astrocyte (see Fig. 5.5A2 & B2), filled with the tracer through the patch pipette during 
20 min of whole cell recording (Bedner et al., 2015; Wallraff et al., 2004). Astrocytes 
were identified by the green fluorescence (eGFP) and their typical passive current 
patterns (see Fig. 5.5A1 and B1). The resting membrane potential of astrocytes from 
DH-IV animals was significantly lower than that of astrocytes from DH-I and 
untreated control littermates (UC = -72.5 ± 5.4 mV, n = 20; HT = 74 ± 6.4 mV, n = 35; 
DH-I = -72.7 ± 5.7 mV, n = 39; DH-IV = -76.8 ± 4.1 mV, n = 44, p < 0.05, post hoc 
Tukey HSD; Table 5.2). The input resistance of astrocytes from HT and DH-IV 
animals was significantly higher than that of astrocytes in untreated control 
littermates (UC = 2.2 ± 0.9 MΩ, n = 20; HT = 4.4 ± 2.5 MΩ, n = 35; DH-I = 3.3 ± 1.6 
MΩ, n = 39; DH-IV = 3.8± 1.8 MΩ, n = 39, p < 0.05, post hoc Tukey HSD; see Table 
5.2). 
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Table 5.2 Summary of electrophysiological recording measurements and IGJC  
 Treatment  Membrane potential  Input resistance  Coupled cells 
  n (cells)  n (cells)  n (mice) 
Control  Untreated Control  72.5 ± 5.4 20 2.2 ± 0.9 20 186 ± 49 4 
HT HT = 36 min 74 ± 6.4 35 4.4 ± 2.5 35 89 ± 50 8 
DH-I LPS_P13 or P14, HT P14 
or P15, HT = 36 min  
72.7 ± 5.7 39 3.3 ± 1.6 39 40 ± 18 8 
DH-IV  LPS_P9, HT P11 and 
P12, HT = 60 min  
76.8 ± 4.1 44 3.8 ± 1.8 44 68 ± 45 8 
 
Quantification of interastrocytic biocytin spread revealed that in the hippocampus of 
EFSs mice the number of tracer coupled cells was significantly lower than in the 
hippocampus of untreated control littermates (UC = 186 ± 49 coupled cells, n = 20 
slices from 4 animals; HT = 89 ± 50 coupled cells, n = 35 slices from 8 animals; DH-I 
= 40 ± 18 cells, n = 39 slices from 8 animals; DH-IV = 68 ± 45 coupled cells, n= 44 
slices from 8 animals, p < 0.05, post hoc Tukey HSD; Table 5.2 &Fig. 5.5C). Within 
EFSs treated mice, there was no difference in the number of coupled cells between 
HT, DH-I and DH-IV animals.  
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Figure 5.5 Reduced astrocytic tracer coupling in hippocampal slices from mice 
that experienced EFSs. IGJC in the stratum radiatum of the hippocampal CA1 
subfield, assessed by intercellular diffusion of biocytin, was compared between EFSs 
animals and untreated control littermates. (A1 and B1) Insets represent current 
responses elicited by 50 ms voltage steps from -160 to +20 mV (Vhold = -80 mV). (A2 
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and B2) Representative images showing the extent of biocytin diffusion through the 
astroglial network in EFS animals (B2) and control littermates (A2). (C) Graph 
summarizing the results from the tracer coupling. In EFS mice, IGJC was 
significantly reduced. Calibration: 10 ms, 5 nA. Scale bar = 50 µm. Asterisk indicates 
p < 0.05 (post hoc Tukey HSD) (Khan et al., 2016). 
 
5.1.6 Protein expression of Cx43 and Cx30 after EFSs 
For astrocytes coupling in the hippocampus two Cx proteins, Cx43 and Cx30 have 
been reported to be responsible (Dermietzel et al., 2000). Reduced astrocyte 
coupling can be caused by reduced protein expression of Cxs as well as by 
modification in their phosphorylation state (John et al., 1999; Pahujaa et al., 2007; 
Solan and Lampe, 2009). To examine protein expression and phosphorylation states 
of Cxs, Western blot analysis was performed using hippocampal protein lysate 
obtained from HT-treated mice 5 d after HT-treatment and untreated control 
littermates. For loading control, membranes were also probed for α-tubulin. 
 
The anti-Cx43 antibody recognized 3 bands within a range of 42-46 kDa (P0, P1 and 
P2), reflecting different phosphorylation states of Cx43 protein (see Fig. 5.6A). Total 
amount of Cx43 protein was significantly reduced in the hippocampus of HT-treated 
mice as compared to untreated control littermates (Cx43 / α-tubulin ratio: UC = 0.54 
± 0.08 vs. HT = 0.35 ± 0.07, n= 3 animals each, p < 0.05, T- test; Fig. 5.6B).  
 
Separate quantification of Cx43 P0, P1 and P2 bands revealed that there was no 
difference in the fractional contribution of P0 band to the total protein (fractional 
contribution of P0: UC = 79.8 ± 2.3 % vs. HT = 66.8 ± 8.2 %, p = 0.057, T- test; Fig. 
5.6C). The fractional contribution of the P1 and P2 bands to the total protein was 
significantly higher in HT-treated mice than in control littermates (fractional 
contribution of P1 and P2: UC = 14.9 ± 3.9 % vs. HT = 31 ± 1.3 %, p < 0.05, T- test; 
Fig. 5.6D). This observation indicates that HT-treatment induced not only a reduction 
of Cx43 expression but also alterations in the Cx43 phosphorylation status.  
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Figure 5.6 Cx43 protein levels in the hippocampus of mice that experienced 
EFSs. (A) Cx43 levels in hippocampal lysates prepared from immature mice 5 d after 
HT-treatment and untreated control littermates. α-tubulin was used as a loading 
control. (B) Quantification of the Western blots revealed that Cx43 protein levels 
were significantly reduced in HT-treated mice compared to untreated control 
littermates (n = 3 animals). (C) There was no difference in the P0 fraction of total 
Cx43 protein between HT treated and untreated control animals. (D) The fractional 
contribution of the P1 and P2 bands to the total protein was significantly higher in HT 
mice than in controls. Asterisks indicate p < 0.05 (T-test). 
 
The anti-Cx30 antibody recognized a band at 30 kDa (Fig. 5.7A), and there was no 
significant difference in the amount of total Cx30 protein between HT-treated and 
untreated control littermates (Cx30 / α-tubulin ratio: UC = 0.28 ± 0.11 vs. HT = 0.33 ± 
0.11, n = 3 animals each, p = 0.6, T-test; Fig. 5.7B). 
 
Results 
 
 
75 
 
 
Figure 5.7 Cx30 protein levels in the hippocampus of mice that experienced 
EFSs. (A) Cx30 levels in hippocampal lysates prepared from immature mice 5 d after 
HT-treatment and from untreated controls. α-tubulin was used as a loading control. 
(B) Quantification of the Western blots revealed that Cx30 protein levels were not 
different between HT-treated and control mice (n = 3 animals). 
 
Together, these data suggest that reduced expression of Cx43 protein and / or 
changes in its phosphorylation pattern account for the decreased astrocyte gap 
junctional communication in HT-treated mice. 
 
5.1.7 Generation of unprovoked spontaneous generalized 
seizures after EFSs 
It has been reported that FSs in early childhood in human can lead to epilepsy in 
later life (MacDonald et al., 1999; Vestergaard et al., 2007). In animal models it has 
been shown that EFSs during early age increase the susceptibility for seizure 
generation (Dube et al., 2000). A former PhD student from our laboratory has 
already shown that HT-treatment (36 min) of immature hGFAP-eGFP mice at P14 or 
P15 caused unprovoked spontaneous generalized seizure in a proportion of animals 
(Dupper, 2014). To assess the development of spontaneous generalized seizure 
after DH-treatment, telemetric EEG transmitters were implanted into animals two 
months after DH-treatment and the occurrence of generalized seizures was 
investigated via continuous telemetric EEG recording and video monitoring over a 
period of two weeks. One out of 19 hGFAP-eGFP animals (including all conditions 
for EFSs) showed generalized seizure (Fig. 5.8 and Fig. 5.9). Among C57Bl6J mice 
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one out of 9 animals (including both condition for DH-treatment) displayed 
generalized seizures with a frequency of 6 seizures / day. 
 
 
Figure 5.8 Summary of treatment and seizure activity. Mice from two genetic 
back-grounds were used in the experiments. EFSs were generated in these mice 
under different conditions regarding age, LPS treatment and duration of HT-
treatment. Two months after EFSs generation, the animals were investigated for 
unprovoked spontaneous seizure activity. HT-treatment (36 min) and EEG 
recordings of immature hGFAP-eGFP mice at P14 or P15 were performed by 
(Dupper, 2014). 
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Figure 5.9 Example of an EEG trace during a spontaneous generalized seizure 
in a DH-treated hGFAP-eGFP mouse. In one out of 19 EFSs treated animals 
spontaneous generalized seizures were observed. The EEG recordings were 
performed 2 months after EFSs generation. 
 
5.2 The role of TAK1 in epilepsy 
5.2.1 TAK1 activation in astrocytes 
In previous studies it has been observed that astrocytes are activated in response to 
noxious stimuli and can elicit pro- as well as anti-inflammatory response (Sofroniew 
and Vinters, 2010). During inflammatory response, inflammatory mediators like NF-
κB are activated which in turn initiate transcription of inflammatory cytokines (Hayden 
et al., 2006). TAK1 is activated by phosphorylation and is an upstream modulator of 
NF-κB activation (Sato et al., 2005; Shim et al., 2005). 
 
To investigate the seizure-induced activation of TAK1 in astrocytes, status 
epilepticus was induced by uni lateral intracortical kainate injection and 
immunofluorescence staining was performed at different time points (4 hpi, 1 dpi and 
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5 dpi). Activated TAK1 (p-TAK1) could not be detected in astrocytes at none of the 
investigated time points (Fig. 5.10; data for 4 hpi and 1 dpi not shown). 
 
 
Figure 5.10 p-TAK1 / S100ß / DRAQ5 triple-staining in the mouse 
hippocampus. Slices were prepared from brains of animals perfused at 5 d after 
kainate-induced status epilepticus. The occurrence of activated TAK1 in astrocytes 
was assessed by S100β (green) / p-TAK1 (red) / DRAQ5 (blue) triple staining. P-
Tak1 was not found to be present in astrocytes at this time point. Scale bar = 50 µm.  
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5.2.2 TAK1 activation in microglia 
Microglia are the major innate immune cells in the CNS (Kreutzberg, 1996). These 
cells quickly activate in response to DAMPs and PAMPs (Heneka et al., 2014; Town 
et al., 2005), migrate to and accumulate in regions of injury and / or degeneration 
(Domercq et al., 2013). Activated microglia produce and release inflammatory 
cytokines like IL-1β, TNF-α, IFN-γ and chemokines (Banati et al., 1993; Smith et al., 
2012). These inflammatory cytokines are produced and released as a consequence 
of NF-κB activation (Hayden et al., 2006). NF-κB activation has been suggested to 
be modulated by activation of TAK1 (Sato et al., 2005; Shim et al., 2005). It has been 
shown that TAK1 deletion and / or inhibition can result in reduced inflammatory 
response (Goldmann et al., 2013; Zhang et al., 2015). 
 
Therefore, to investigate TAK1 activation in microglia, status epilepticus was induced 
by unilateral intracortical kainate injection. Immunofluorescence staining was 
performed at different time points (4 hpi, 1 dpi and 5 dpi). TAK1 activation was 
observed in microglia (Fig. 5.11; data for 4 hpi and 1 dpi not shown). Fluorescence 
intensity of p-TAK1 increased significantly on ipsilateral side 5 dpi when compared to 
untreated control and to the ipsi- and contralateral sides of mice 4 hpi and 1 dpi 
(fluorescence intensity of p-TAK1: UC = 80 ± 23 a.u.; 4 hpi contra = 48 ± 6 a.u.; 4 hpi 
ipsi = 52 ± 4 a.u.; 1 dpi contra = 69 ± 17 a.u.; 1 dpi ipsi = 80 ± 9 a.u.; 5 dpi contra = 
113 ± 34 a.u.; 5 dpi ipsi = 151 ± 30 a.u.; 9 sections from 3 animals for each 
condition, p < 0.05, post hoc Tukey HSD; Fig. 5.12A). The number of microglia cells 
showing TAK1 activity was significantly higher on the ipsi- as well as contralateral 
side 5 dpi when compared to the untreated control and to the ipsi- and contralateral 
sides of mice 4 hpi and 1 dpi (number of microglia cells / mm3 showing TAK1 activity: 
UC = 18298 ± 2565; 4 hpi contra = 9773 ± 8543; 4 hpi ipsi = 9618 ± 8381; 1 dpi 
contra = 13496 ± 465 ; 1 dpi ipsi = 14428 ± 1231; 5 dpi contra = 66709 ± 8394; 5 dpi 
ipsi = 90755 ± 25908; 9 sections from 3 animals for each condition, p < 0.05, post 
hoc Tukey HSD; Fig. 5.12B). 
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Figure 5.11 p-TAK1 / Iba1 / DRAQ5 triple-staining in the mouse hippocampus. 
Slices were prepared from brains of animals perfused 5 dpi after kainate induced 
status epilepticus. Activated TAK1 in microglia was detected by Iba1 (green) / p-
TAK1 (red) / DRAQ5 (blue) triple staining. TAK1 was activated in Iba1-positive cells 
(microglia). Scale bar = 50 µm. 
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Figure 5.12 Quantification of TAK1 activation in microglial cells. TAK1 activation 
in microglia increased 5 dpi. A) Fluorescence intensity of p-TAK1 increased 
significantly on the ipsilateral side 5 dpi. B) The number of microglia cells showing 
activated Tak1 was significantly increased on ipsi as well as on contralateral sides 5 
dpi. Quantification was performed in a volume of 150.39 x 150.39 x 19 µm3 in the 
stratum radiatum. Asterisks indicate p < 0.05 (post hoc Tukey HSD). 
 
5.2.3 Genotyping of the TAK1KO animals 
To investigate the role of TAK1 in epileptogenesis, TAK1KO animals were used. For 
genotyping, animals were tested for the presence of the Tak1f l/f l allele (lower row) 
and the Cx3cr1CreER transgene (upper row). Mouse number 1, 3, 4, 5, 6, 8 and 9 for 
instance, had a Tak1f l/f l as well as Cre-recombinase allele. In mice with this genotype 
TAK1 could be knocked out by TAM administration. Mouse number 2 and 7 had a 
Tak1f l/f l allele but lacked the Cre-recombinase and could therefore be used as a 
control. 
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Figure 5.13 Genotyping PCR of the Cx3cr1CreER:Tak1fl/fl mouse line. Deletion of 
the TAK1 gene was monitored by genotyping PCR. As heterozygous animals were 
crossed, all the animals showed a WT allele. Mouse number 1, 3, 4, 5, 6, 8 and 9 
had alleles for Tak1f l/f l and Cre-recombinase. Mouse number 2 and 7 lacked the 
allele for Cre-recombinase. 
 
5.2.4 Microglia activation in TAK1KO animals 
Microglia activation was investigated after status epilepticus induced by unilateral 
intracortical kainate injection in TAK1KO and their Cre-negative (control) littermates. 
Five days after injection, animals were perfused and cryosections of the brains were 
stained with anti-Iba1 antibodies. Alterations in microglial morphology (hypertrophic 
cell bodies and processes) were much less in TAK1KO animals than in their control 
littermates (Fig. 5.14A). Also, Iba1 immunoreactivity was significantly less on the 
ipsilateral side of TAK1KO mice than on the ipsilateral and contralateral side of Cre-
negative littermates 5 dpi (area occupied by Iba1: TAK1KO ipsi = 0.802 ± 0.313 %; 
TAK1KO contra = 1.2 ± 0.55 %; contr. ipsi = 3.089 ± 1.223 %; contr. contra = 3.076 ± 
0.6 %, n = 9 slices from 3 animals for each condition, p < 0.05, post hoc Tukey HSD; 
Fig. 5.14B) as well as the number of Iba1-positive cells observed in a volume of 289 
x 289 x 19 µm3 was significantly lower in TAK1KO mice compared to Cre-negative 
littermates (number of Iba1-positive cells: TAK1KO ipsi = 50902 ± 4244; TAK1KO 
contra = 53703 ± 7397; contr. ipsi = 97604 ± 10258; contr. contra = 73868 ± 4679, n 
= 9 slices from 3 animals for each condition, p < 0.05, post hoc Tukey HSD; Fig. 
5.14C). 
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Figure 5.14 Microglia activation 5 dpi. Slices were prepared from brains of animals 
perfused 5 dpi. Microglia activation could be detected by Iba1 (green) / Hoechst 
(blue) double staining. A) Decreased microglia activation was observed in TAK1KO. 
B) The area occupied by Iba1-positive cells was significantly lower on ipsilateral side 
in TAK1KO mice and C) the number of Iba1-positive cells were significantly lower in 
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TAK1KO animals when compared to their control littermates. Scale bar = 50 µm. 
Asterisks indicate p < 0.05 (post hoc Tukey HSD). s.o. = stratum oriens; s.p. = 
stratum pyramidale; s.r. = stratum radiatum. 
 
5.2.5 Kainate-induced seizure activity in TAK1KO animals 
To investigate the seizure frequency in TAK1KO animals, EEG recordings with video 
monitoring were performed for one month after uni lateral intracortical kainate 
injection in TAK1KO and control animals. Spontaneous seizure activity was 
assessed from 3 dpi, when the EEG recordings became stable , to 30 dpi. The 
seizure frequency was significantly lower in 4 out of 6 TAK1KO animals when 
compared with the controls (average seizures / d over a period of one month: 
TAK1KO = 1 ± 0.36 vs. contr. = 2.6 ± 0.7, n = 4 and 5 animals, respectively, p < 
0.05, T-test; Fig. 5.15A). To identify the time point when TAK1KO and control 
animals start to show differences in seizure frequency, EEG data was analyzed in 
steps of 5 d duration over a period of a month. The seizure frequency for TAK1KO 
and control animals was averaged over five days. In the beginning there was no 
difference in seizure frequency between TAK1KO and controls but from day 11-15 
the seizure frequency started decreasing for TAK1KO animals and increasing for 
control mice (Fig. 5.15B). The number of seizures / day was significantly lower in 
TAK1KO animals than in their Cre-negative littermates, averaged for the duration 
between 16-20 and 21-25 d (seizure / d averaged over a duration of 5 d: 3-5 d, 
TAK1KO = 1.25 ± 0.83 vs. contr. = 0.8 ± 0.5; 6-10 d, TAK1KO = 1.5 ± 0.52 vs. contr. 
= 1.28 ± 0.48; 11-15 d, TAK1KO = 1.18 ± 1.29 vs. contr. = 2.77 ± 0.87; 16-20 d, 
TAK1KO = 1.02 ± 0.51 vs. contr. = 3.35 ± 0.7; 21-25 d, TAK1KO = 0.75 ± 0.25 vs. 
contr. = 3.2 ± 1.32; 26-30 d, TAK1KO = 0.55 ± 0.3 vs. contr. = 3.74 ± 3.51; n = 4 and 
5 animals, respectively, p < 0.05, T-test). 
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Figure 5.15 Seizure frequency after kainate-induced status epilepticus in 
control and TAK1KO mice. A) Generation of unprovoked spontaneous generalized 
seizures analyzed over a period of one month after kainate-induced status 
epilepticus. The seizure frequency was significantly reduced in TAK1KO mice 
compared to control littermates over a period of one month. B) Average number of 
seizures analyzed for durational steps of 5 d over a period of one month after 
kainate-induced status epilepticus. Number of seizures increased for control mice 
and decreased for TAK1KO littermates 10 days after status epilepticus. The 
difference in the number of seizures was significantly different at days 16-20 and 21-
25. Asterisks indicate p < 0.05 (T-test). 
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6 Discussion 
6.1 Consequences of EFSs on the hippocampal 
astrocytic network 
6.1.1 EFSs generation 
It has been reported that 20-60% of patients suffering from intractable epilepsy had a 
history of prolonged FSs during early childhood (Bender et al., 2004; McClelland et 
al., 2011). In Europe and the US, 2-4 % of all children experience at least one FS 
before the age of 5 years (Hauser, 1994). The occurrence of FSs varies in different 
geographical locations; in Japan 8 % (Hauser, 1994; Tsuboi, 1984) and in China 1 % 
(Hauser, 1994) of children experience seizures before the age of 5 years. In some 
follow-up studies it has been found that 2.4 % of the children having simple FSs and 
6 to 8 % of the children experiencing complex FSs are at a higher risk for generation 
of unprovoked seizures and epilepsy development (Annegers et al., 1987; Hauser, 
1994). It can be expected that FSs during early childhood cause some irreversible 
damage to the brain which in later age can lead to epilepsy. In rats generation of 
spontaneous seizures as a consequence of EFSs has been reported (Dube et al., 
2006). To investigate the effects of FSs on brain during early childhood, EFSs were 
induced in immature mice. To study the effects of inflammation, age, genotype and 
duration of fever on FS generation, HT was induced under different conditions  in 
young mice from two different genetic back-grounds summarized in Table 5.1 
(section 5.1.1). 
 
The duration of EFSs in our approach was 36 min and that corresponds to the 
duration of most of the FSs in chi ldren (Shinnar et al., 2008). In some cases, 
however, the FSs last longer than 36 min in children (Boggs and Waterhouse, 2001). 
Therefore in this study the duration of the HT-treatment was also increased to 60 min 
in some experiments while keeping all the other conditions the same. In all EFS 
experiments, HT-treatment did not cause dehydration, as the decrease in average 
body weight was less than 5 % (see Table 5.1). Mild, moderate and severe 
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dehydration in children is defined as a body weight loss greater than 5 %, 10 % and 
15 % of total body weight, respectively (Portale et al., 2002). 
 
The threshold temperature for EFSs in pups varied between 39.4 ± 0.2 °C and 40.7 
± 0.4 °C with no significant difference between different conditions (section 5.1.1 & 
Table 5.1), and it was slightly less than 40.8 °C as reported in rats (Dube et al., 
2000) which can be due to differences in species and experimental setup. At the 
threshold temperature animals showed first sudden immobility, and it has been 
shown that first spikes on EEGs appear during this phase (Dube et al., 2000). During 
HT-treatment behavioral scoring of animals was recorded and scaled ( Table 4.1; 
van Gassen et al., 2008). In all experiments, animals showed motor automatisms 
that involved movement of distal segments of hands, feet, mouth and tongue. These 
automatisms are typically observed in TLE but sometimes can also be found with 
frontal lobe seizures (Tufenkjian and Luders, 2012; Vendrame et al., 2011). During 
HT-treatment animals showed face automatisms involving chewing, swallowing and 
grooming. Clonic seizures were also observed in some mice and these clonic 
seizures are probably secondary generalized seizures, which originate also from the 
temporal lobe. These data suggest that in this study EFSs observed in animals 
originated mostly from the temporal lobe. 
 
Under different conditions animals showed differences in frequency, intensity, 
duration and stage (Table 4.1) of EFSs, but no differences were observed in EFSs 
between two episodes of HT-treatment under the same conditions on consecutive 
days (section 5.1.1). LPS administration one day before HT-treatment increased 
frequency, intensity, duration and stage (Table 4.1) of EFSs (see section 5.1.1). It 
has been already reported that postnatal LPS administration increases susceptibility, 
intensity and frequency of seizures as observed in rats and mice (Auvin et al., 2010; 
Eun et al., 2015; Galic et al., 2008). Increasing the duration between LPS 
administration and HT-treatment even worsened EFSs, and EFSs continued to occur 
even after stopping the protocol after 36 min. It has been suggested that LPS 
decreases K+ buffering via causing reduction in IGJC (Bedner et al., 2015) which can 
consequently increase the susceptibility to seizure generation. In addition, systemic 
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LPS administration induces peripheral inflammation that leads to neuroinflammation 
and can subsequently cause oxidative stress in the hippocampus which might 
increase the susceptibility to seizures (Ho et al., 2015). LPS administration triggers 
an inflammatory response which leads to the release of inflammatory cytokines like 
IL-1β and TNF-α (Bossu et al., 2012; Qin et al., 2007). Moreover, the damage 
produced by these inflammatory cytokines and oxidative stress might increase by 
increasing the duration between the two hits; therefore, it seems that the duration 
between LPS administration and HT-treatment can affect EFSs as observed in the 
present study. Altogether, it can be suggested that LPS-induced inflammation 
increases the susceptibility of mice to hyperthermic seizures. 
 
The use of mice in the experiments (DH-III - DH-VI) at younger age while keeping all 
other conditions similar resulted in decreased hyperactive behavior, jumping and 
rearing. This might be due to the small body size of animals, as except hyperactivity, 
the younger animals showed seizures and / or behavior similar to the older animals 
during HT-treatment (section 5.1.1). After 36 min, hGFAP-eGFP animals started to 
show stage IV seizures (tonic-clonic convulsions), and the intensity of these seizures 
constantly increased toward the end of the protocol. Even after stopping the protocol 
and when back with the mother, stage IV seizures were observed. hGFAP-eGFP 
mice displayed stage IV seizures only in DH-IV experiments, in which the duration of 
HT-treatment was extended to 60 min. Here they showed continuous tonic clonic 
contractions of fore and hind limb with loss of consciousness. As differences in 
genotype can affect EFS onset and it has been shown that C57Bl6J mice are more 
sensitive to this type of seizures (van Gassen et al., 2008), C57Bl6J mice were used 
for EFSs generation. In these animals, there was an increase in intensity, frequency 
and duration of EFSs. These animals showed stage I-IV seizures during the 
experiment and stage IV seizures when back with the mother. C57Bl6J showed 
febrile status epilepticus of 8-10 min towards the end of the protocol in the 
experiments (DH-VI) in which HT was induced for 60 min (see section 5.1.1). In 
conclusion, intensity, duration or frequency of FSs seem to be dependent on the 
genotype and duration of HT-treatment and / or fever. 
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6.1.2 EFSs do not cause neuronal degeneration  
Neuronal cell death as an effect of seizures has been revealed in animal models of 
epilepsy (Jiang et al., 1999; Pitkanen et al., 2002, Bedner et al., 2015). Similar to the 
situation in human TLE, pyramidal neurons in the CA1, CA3 and hilus were 
susceptible to neuronal cell death in the experimental models (Freund et al., 1992; 
Nadler, 1981). Previously, neuronal degeneration in the hippocamapal CA1 
pyramidal layer has been shown to occur as early as 6 h post kainate injection in a 
mouse model of epilepsy (Bedner et al., 2015). However, in the present study no 
neuronal degeneration was observed at two different time points (6 h and 5 d) after 
EFSs (Fig. 5.1) (Khan et al., 2016). Also, there was no change in the density of 
pyramidal neurons in the CA1 region of stratum pyramidale 5 d after EFSs (Fig. 
5.2B). Consistent with our findings it has been shown that EFSs induced by HT-
treatment in rats resulted in enhanced hippocampal excitability in the absence of 
neuronal cell death (Bender et al., 2003; Dube et al., 2010). It is known from 
previous studies that the immature hippocampus is extraordinarily resistant to 
seizure-induced neuronal cell death (Haas et al., 2001) and prolonged status 
epilepticus is a prerequisite for neuronal degeneration (Sankar et al., 1998; 
Thompson et al., 1998). Further, it has been reported that fat-rich maternal milk can 
be protective against excitotoxicity (Sullivan et al., 2003). Because, the pups were 
placed with their mother after EFS generation and they were dependent on their 
mother’s milk, it can be expected that the fat-rich maternal milk might have provided 
a protection from neuronal degeneration as a consequence of EFSs. 
 
6.1.3 EFSs lead to microglia activation 
Microglia are the resident macrophages of the brain. Under physiological conditions 
these cells continuously scan their surrounding tissue with their highly motile and  
ramified processes (Nimmerjahn et al., 2005). Due to this behavior these cells can 
rapidly respond to injury (Cherry et al., 2014; Rock et al., 2004) and become 
activated. The activated microglia become hypertrophic, retract their processes, 
extend filopodia, and increase their proliferation and migration. In addition to 
clearance of apoptotic cells and phagocytosis of cellular debris, activated microglia 
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release pro-inflammatory cytokines such as IL-1β, IL-6 and TNF-α (Smith et al., 
2012; Vezzani et al., 2008). 
 
Five days after EFSs, microglial cells with altered morphology (hypertrophic cell 
bodies and processes) were observed in the hippocampi of HT-treated mice as 
compared to room temperature-treated and untreated control littermate (Fig. 5.3A). 
Moreover, Iba1 immunoreactivity as well as the number of Iba1-positive cells was 
significantly increased in the hippocampi of HT-treated mice compared to the 
controls (see Fig. 5.3B, C) (Khan et al., 2016). In similar studies, microglia activation, 
increase in the expression and release of pro-inflammatory cytokines has been 
reported (Eun et al., 2015; Jung et al., 2011; Patterson et al., 2015). Furthermore, 
microglia activation has been observed as a result of status epilepticus induced by 
injection of chemoconvulsants (Avignone et al., 2008; Eyo et al., 2014, Bedner et al., 
2015), and in patients suffering from intractable epilepsy (Beach et al., 1995). Also, 
increase in inflammatory cytokine release after FSs in children has been observed 
(Choi et al., 2011). In addition to PAMPs and DAMPs, it has been suggested that the 
release of ATP from hyperactive neurons can attract and activate microglia via 
purinergic signaling (Eyo et al., 2014; Haynes et al., 2006; Dissing-Olesen et al., 
2014). 
 
The present study confirms previous reports that EFSs induce CNS inflammation. 
Though astrocytes have been shown to contribute to the inflammatory response 
(Dube et al., 2010; Vezzani et al., 2008), activated microglia are the major source of 
inflammatory cytokines such as IL-1β, IL-6 and TNF-α (Smith et al., 2012; Vezzani et 
al., 2008). These inflammatory cytokines can modulate neuronal activity directly by 
affecting neuronal receptors and / or indirectly by altering glial function (Vezzani and 
Viviani, 2015). IL-1β and TNF-α were found to reduce IGJC in acute brain slices as 
well as in cultured astrocytes (Bedner et al., 2015; Meme et al., 2006). Also, IL-1β 
has been shown to reduce Kir4.1 expression in astrocytes (Zurolo et al., 2012). 
Reduction in IGJC and Kir4.1 dysfunction has been associated with epileptogenesis 
(Steinhäuser et al., 2012; Steinhäuser et al., 2016). These inflammatory cytokines 
also inhibit glutamate uptake by astrocyte (Hu et al., 2000; Zou and Crews, 2005) 
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and increase glutamate release from astrocyte and microglia (Bezzi et al., 2001; 
Takeuchi et al., 2006). This glutamate release activates slow inward currents , which 
might generate epileptiform activity through synchronization of pyramidal neurons of  
the hippocampus (Carmignoto and Fellin, 2006). IL-1β modulates NMDA receptor 
activity (Viviani et al., 2003; Yang et al., 2005), which results in neuronal 
hyperexcitability (Zhang et al., 2008; Zhang et al., 2010) and promotes seizure 
generation (Balosso et al., 2008). TNF-α increases hyperexcitability by exocytosis of 
AMPA receptors (Beattie et al., 2002; Stellwagen et al., 2005) and reduces inhibitory 
transmission through endocytosis of GABA-A receptors (Stellwagen et al., 2005). 
Activated microglia not only influence other cell types through release of cytokines 
but also through cell-cell interaction via gap junctions (Kielian, 2008). 
 
6.1.4 Effect of EFSs on astrogliosis 
In response to traumatic insults astrocytes undergo physiological, morphological and 
biochemical changes (Wilhelmsson et al., 2006), these changes are collectively 
termed as “reactive astrogliosis” (Sofroniew and Vinters, 2010). Reactive astrogliosis 
is a continuous progressive process, but for better understanding it was classified 
into three categories: mild to moderate reactive astrogliosis; severe diffuse reactive 
astrogliosis and severe reactive astrogliosis with compact glial scar formation 
(Sofroniew and Vinters, 2010). Mild reactive astrogliosis is characterized by GFAP 
up-regulation, hypertrophy of cell body and processes, little or no astrocyte 
proliferation, no overlap of processes of neighboring astrocytes and preservation of 
individual domains (Wilhelmsson et al., 2006). In sever diffuse reactive astrogliosis, 
there is dramatic up-regulation of GFAP expression, intense hypertrophy of cell body 
and processes, increased astrocyte proliferation resulting in overlap of processes of 
neighboring astrocytes and loss of individual domains. In severe reactive astrogliosis 
with compact glial scar formation the conditions associated with severe diffuse 
reactive astrogliosis are worsened along with dense, narrow and compact scar 
formation (Wanner et al., 2013). These scars formed around damaged tissue limit 
the infiltration of infectious agents, inflammatory cells and act as a neuroprotective 
barrier (Bush et al., 1999; Faulkner et al., 2004; Herrmann et al., 2008) . Also, 
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astrocytes communicate profoundly with microglia, and can exert both inflammatory 
and anti-inflammatory effects on them (Min et al., 2006; Ovanesov et al., 2008). 
 
In this study, five days after EFSs, there was no difference in the morphology of 
GFAP positive cells if compared to untreated control littermates (Fig. 5.4A). Also, no 
difference was observed in the area occupied by GFAP-positive cells between EFS-
induced mice and untreated control littermates (Fig. 5.4B). In a similar study 
performed in rats, acute astrogliosis 24 h after EFSs has been observed but it 
returned to normal state after 96 h (Patterson et al., 2015). Dube et al. (2010) have 
shown that reactive astrocytes are more abundant 6 h after EFSs and are the source 
of IL-1β, but the morphology of astrocytes 24 h after EFSs was typical for their 
resting state. As in mild reactive astrogliosis, there is little or no reorganization of 
tissue architecture (Sofroniew and Vinters, 2010), and if the cause of reactive 
astrogliosis is resolved, the astrocytes return to their healthy state (Sofroniew and 
Vinters, 2010). Therefore, it is very likely that reactive astrogliosis observed early 
after EFSs (Dube et al., 2010) is of the mild reactive astrogliosis type and it explains 
the absence of reactive astrogliosis five days after EFSs as observed in the present 
study. 
 
6.1.5 EFSs induce a reduction in IGJC 
In the hippocampus astrocytes are connected with each other via gap junctions 
formed by Cx43 and Cx30 (Giaume and McCarthy, 1996; Gosejacob et al., 2011). 
These gap junctions serve as intercellular conduits between cells and directly 
connect the cytoplasm of different cells. As through these gap junctions ions, 
metabolites, glucose, and small molecules can pass from one cell to another, the 
astrocytic network plays a vital role in homeostatic regulation of extracellular pH, K+, 
and glutamate levels (Kielian, 2008). Reduction in IGJC has been suggested to be 
associated with epileptogenesis (Steinhäuser et al., 2012; Steinhäuser et al., 2016). 
 
To investigate the effects of FSs on the astroglial network, IGJC was studied five 
days after EFSs generation. More than 50 % reduction in the IGJC has been 
observed 5 d after EFSs (see section 5.1.5; Table 5.2; Fig. 5.5) (see Khan et al., 
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2016). Previously, loss of IGJC has been shown in human sclerotic hippocampi from 
mTLE patients and in a mouse model of mTLE (Bedner et al., 2015). In addition to 
IL-1β and TNF-α, LPS (which causes the release of these inflammatory cytokines) 
has been shown to reduce IGJC in acute brain slices as well as in cultured 
astrocytes (Bedner et al., 2015; Liao et al., 2013; Meme et al., 2006). Increased 
levels of these cytokines have been reported in the hippocampus of EFS animals 
(Dube et al., 2010) and in CSF, plasma and serum of chi ldren with FSs (Choi et al., 
2011; Haspolat et al., 2002; Tutuncuoglu et al., 2001; Virta et al., 2002b) . LPS-
induced inflammation in mice reduced the IGJC by 50 % (Bedner et al., 2015). In toll 
like receptor 4 knockout animals, kainate-induced status epilepticus did not cause 
reduction in IGJC (Bedner et al., 2015). These inflammatory cytokines are released 
from activated microglia and astrocytes (Wang et al., 2015). Also, reduced IGJC has 
been reported in the presence of activated microglia (Faustmann et al., 2003). In the 
present study microglia activation was observed 5 d after EFSs (section 5.1.3), at the 
same time point when reduction in IGJC was detected (section 5.1.5). The findings 
reported in the previous studies and the observations made in the present study 
suggest that EFS-induced reduction in IGJC is caused by pro-inflammatory cytokines 
released from activated microglia.  
 
During hyperactivity, the extracellular level of K+ increases to 10-12 mM from the 
resting level of 3 mM (Heinemann and Lux, 1977; Steinhäuser et al., 2012). The 
level of K+ is balanced in the extracellular space via two distinct mechanisms: K+ 
uptake and spatial K+ buffering (Kofuji and Newman, 2004). K+ is taken up by the 
astrocytes at the site of higher extracellular K+ level and transferred via the astroglial 
syncytium to sites of lower K+ concentration (Kofuji and Newman, 2004). Impairment 
in the clearance of extracellular K+ can lead to neuronal depolarization and 
consequently to neuronal hyperexcitability (Steinhäuser et al., 2012). In a mouse 
model of mTLE, reduction in IGJC and impaired K+ buffering has been observed 
before the appearance of neuronal degeneration, suggesting that reduction in IGJC 
is rather a cause than the consequence of epileptic seizures (Bedner et al., 2015). In 
conclusion, it is reasonable to assume that EFS-caused reduction in IGJC can 
trigger neuronal hyperexcitability due to insufficient clearance of extracellular K+. 
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This glial dysfunction might represent an important factor in the course of 
epileptogenesis. 
 
6.1.6 Protein expression of Cx43 and Cx30 
Five days after EFSs, reduction in IGJC was observed (section 5.1.5). Dermietzel 
and colleagues have reported that in the hippocampus two Cx proteins, i.e. Cx43 
and Cx30, are responsible for IGJC between astrocytes (Dermietzel et al., 2000). 
There are only a few studies performed to understand the regulation of Cx30, 
however, Cx43 has been investigated in detail. There are at least four possible ways, 
through which Cx43-mediated functional coupling can be regulated: expression of 
the Cx43 protein (John et al., 1999), its phosphorylation (Pahujaa et al., 2007; Solan 
and Lampe, 2009), cellular localization and internalization, and / or degradation of 
the Cx43 protein (Liao et al., 2013). Studies on myocytes and cultured astrocytes 
have provided evidence to support the assumption that Cx43 channels of a cell can 
be replaced within 1 to 3 h (Beardslee et al., 1998; Hertzberg et al., 2000; Laird et 
al., 1991) and post-translational modifications are usually rapid (Li et al., 1998; Nagy 
and Li, 2000). 
 
WB analysis was performed to study the expression of Cx proteins and their 
phosphorylation status after EFS generation in the context of uncoupling. Expression 
of total Cx43 protein was significantly reduced in the hippocampus of EFSs mice 
compared to untreated control littermates, 5 d after EFSs (Fig. 5.6). It has been 
revealed that expression of Cx43 was significantly reduced in astrocytes in 
cocultures containing activated microglia compared with cocultures containing 
quiescent microglia (Faustmann et al., 2003). IL-1β triggers loss of Cx43 protein 
(Haghikia et al., 2008a; John et al., 1999; Meme et al., 2006) via down-regulation of 
Cx43 mRNA in cultured human fetal astrocytes (John et al., 1999). Reduced 
expression of Cx43 can be caused by two mechanisms: reduction in transcription 
and / or translation (John et al., 1999) or by increased degradation (Liao et al., 
2013). It has been reported that inflammation can cause degradation of Cx43 via 
ubiquitination (Liao et al., 2013). Altogether, it can be suggested that activated 
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microglia and inflammatory cytokines released from activated microglia might be the 
cause of reduced Cx43 expression after EFS generation in the present study. 
 
In addition to the decreased total Cx43 protein, altered phosphorylation of Cx43 has 
been observed (Fig. 5.6D). The fractional contribution for P1 and P2 phosphorylation 
state of Cx43 protein to total Cx43 protein was significantly increased 5 d after EFSs 
generation in EFSs animals than untreated control littermates (Fig. 5.6D), while the 
expression for P0 phosphorylation state of Cx43 remained unchanged (Fig. 5.6C). 
There was no change in the expression of total Cx30 5 d after EFSs generation (Fig. 
5.7). These data suggest that the reduction in IGJC 5 d after EFSs generation might 
be the result of reduction in Cx43 protein and / or alteration in its phosphorylation 
status. 
 
It is generally unclear whether changes in coupling and in expression of Cx43 have 
protective or harmful effects. There is experimental evidence that gap junction-
mediated coupling contributes to a greater distribution of stress molecules and 
therefore can cause higher neuronal damage (de Pina-Benabou et al., 2005; 
Frantseva et al., 2002; Kielian, 2008). In addition, high neuronal activity, such as 
epileptic seizures, require an increased supply of energetic metabolites such as 
glucose and lactate. However, this is possible only with an intact astrocytic network  
(Rouach et al., 2008). These findings point to a pro-epileptic function of the astrocytic 
network. On the other hand, there are also contradictory studies which tend to favor 
an anti-epileptic function of the astrocytic network, as mice with reduced Cx43 
expression experience greater damage after ischemia (Nakase et al., 2003). In 
cultured astrocytes it has been observed that gap junctional communication 
mediated by Cx43 provides resistance against cellular death from oxidative stress 
(Le et al., 2014). In acute brain sections it has been shown that reduced IGJC can 
cause a reduced K+ buffering which leads to hyperexcitability of neurons and may 
result in further damage (Wallraff et al., 2006). Although these inconsistencies might 
be due to differences in methods and models, we raised in our group strong 
evidence that uncoupling plays an essential role in the early phase of 
epileptogenesis. This assumption is based on the results from our epilepsy model 
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that uses intracortical kainate injections (Bedner et al., 2015). In this study we found 
that uncoupling of astrocytes is one of the first events that occur very early after 
kainate administration (Bedner et al., 2015) and actually results in decreased K+ 
buffering which can lead to hyperexcitability of the neurons and can generate 
epileptiform activity (Steinhäuser et al., 2016). 
 
6.1.7 Generation of recurrent spontaneous generalized 
seizures after EFSs 
Both retrospective and prospective studies have suggested a link between FSs and 
epilepsy (Bender et al., 2004; French et al., 1993; Shinnar, 2003). Also in animal 
models EFSs have been shown to increase susceptibility for seizures  (Dube et al., 
2000) and in some studies it has been revealed that EFSs in rats resulted in 
generation of unprovoked spontaneous seizures (Dube et al., 2006; Dube et al., 
2010). Therefore, to investigate the effects of FSs in mice, EFSs were generated 
under different conditions (section 5.1.1; Table 5.1; Fig. 5.8). Previously, a former 
PhD student of our lab induced HT in four hGFAP-eGFP mice, out of which one 
animal showed unprovoked spontaneous seizures (Dupper, 2014). In previous 
studies, it has been reported that postnatal LPS administration increases 
susceptibility, intensity and frequency of seizures as observed in rats and mice 
(Auvin et al., 2010; Eun et al., 2015; Galic et al., 2008). Also, in the present study, 
LPS pre-treatment resulted in an increased intensity and duration of EFSs generated 
via HT-induction (see section 5.1.1). But it did not increase the incidence of epileptic 
animals. Recurrent spontaneous generalized seizures were observed in one out of 
19 hGFAP-eGFP and one out of 9 C57Bl6J mice. It has been shown that the 
incidence of epilepsy development was 35-45 % in rats after experiencing EFSs 
(Dube et al., 2006; Dube et al., 2010). In the present study approximately 7 % of the 
mice developed epilepsy. The lower incidence of seizures may be explained by the 
differences between species (mouse vs. rat) and differences in the experimental 
approach. In addition, EEG recordings were made for a relative short duration (10-14 
days), raising the possibility that in some epileptic animals the seizures were simply 
missed. The probability of developing epilepsy increases with increasing age  
(Hesdorffer et al., 2011), but in the present study EEG recordings were made after 2 
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months and it is, therefore, also possible that some of the animals had not developed 
epilepsy at this time point even when they were susceptible to epilepsy development. 
In this study EFSs were generated with two different HT durations: 36 min and 60 
min. Two animals that became epileptic had experienced EFSs for 36 min. 
Prospective studies in humans have revealed that the risk for developing epilepsy 
increases with duration of FSs (Annegers et al., 1987). Similarly, in animal studies it 
has been shown that with increasing duration of EFSs the probability for epilepsy 
development increases (Dube et al., 2006; Dube et al., 2010). However, we did not 
observe increase in the incidence of epilepsy development with increased duration of 
EFSs and the more plausible explanation for this would be interspecies differences, 
which indeed may be the case as we observed difference in epileptiform activity 
even in two different strains of the mice. It has been suggested that the genetic back-
ground can play a role in epileptogenesis (van Gassen et al., 2008). In the present 
study, it has been observed that EFSs in two strains of mice affect the incidence of 
epilepsy development and the number of seizures observed in epileptic mice. 
Epileptic C57Bl6J mice had 6 times more seizures per day than hGFAP-eGFP mice 
(Fig. 5.8). In a similar study it has been reported that C57Bl6J are more susceptible 
to seizure generation (van Gassen et al., 2008). Furthermore, in prospective studies, 
it has been revealed that 2-10% of children with FSs experience develop epilepsy in 
later life (Shinnar, 2003), which seems to be near to the present study in which 7 % 
of mice showed unprovoked spontaneous seizures after EFSs. Altogether, it can be 
suggested that EFSs under different conditions can lead to unprovoked spontaneous 
seizure generation in mice, and the incidence of epileptic animals is similar to the 
risk factor in children. 
 
6.2 Role of TAK1 in epilepsy 
6.2.1 In astrocytes TAK1 is not activated 
In the CNS inflammatory responses are elicited by astrocytes and microglia. Under 
pathological conditions astrocytes undergo physiological, morphological and 
biochemical changes (Wilhelmsson et al., 2006) and release inflammatory cytokines 
like IL-1β and TNF-α (Dube et al., 2010; Lau and Yu, 2001). Astrocytes express 
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TLRs (Bsibsi et al., 2002), through which they recognize PAMPs and DAMPs (Miller 
et al., 2005). Through TLRs TAK1 is activated in response to PAMPs and DAMPs 
(Irie et al., 2000; Sato et al., 2005), which in turn triggers activation and translocation 
of NF-κB to the nucleus (Sato et al., 2005; Shim et al., 2005), leading to the 
transcription and release of inflammatory cytokines (Hayden et al., 2006). TAK1 is a 
member of the MAPK family (Yamaguchi et al., 1995) and in addition to NF-κB it is 
an upstream modulator of MAPKs (Sato et al., 2005).  
 
To investigate the role of TAK1 in epileptogenesis, TAK1 activation in astrocytes was 
assessed at different time points (4 hpi, 1 dpi and 5 dpi) after kainate-induced status 
epilepticus. Immunofluorescence staining showed that TAK1 was not activated in 
astrocytes (Fig. 5.10). Previously it has been shown that as a consequence of status 
epilepticus molecules like DAMPs, reactive oxygen species, ATP and glutamate are 
released from hyperactive and dying neurons (Meurs et al., 2008) which trigger 
inflammatory response in astrocytes (Liu et al., 2000). Furthermore, IL-1β and TNF-α 
can be released from microglia and these inflammatory cytokines are known trigger 
of inflammatory response in astrocytes (Sofroniew and Vinters, 2010). It has been 
suggested that NF-κB activation is needed for the release of inflammatory cytokines 
like IL-1β (Hayden et al., 2006) and it has been shown that seizure generation in rats 
results in the release of these inflammatory cytokine from astrocytes (Dube et al., 
2010; Lau and Yu, 2001). In various studies it has been reported that NF-κB 
activation and translocation to the nucleus can take place via alternative pathways 
independent of TAK1 activation (Sun, 2011). 
 
Altogether, this data shows that TAK1 is not activated in astrocytes, indicating that 
TAK1 activation is not involved in NF-κB activation and its translocation to the 
nucleus in astrocytes. 
 
6.2.2 TAK1 is activated in microglia 
TAK1 activation in microglia was investigated at different time points (4  hpi, 1 dpi and 
5 dpi) after status epilepticus induced by unilateral intracortical kainate injection. 
Immunofluorescence staining revealed that TAK1 is activated in microglia 5 d after 
Discussion 
 
 
99 
 
kainate (Fig. 5.11). Furthermore, quantitative analysis showed that TAK1 activation 
in microglia and the number of microglia expressing phosphorylated TAK1 
significantly increased 5 d after status epilepticus (Fig. 5.12A & 5.12B). It has been 
suggested that the release of ATP from hyperactive neurons can attract and activate 
microglia via purinergic signaling (Eyo et al., 2014; Haynes et al., 2006; Dissing-
Olesen et al., 2014). As a result of status epilepticus hyperactive neurons release 
excessive glutamate. Microglia have been suggested to express receptors for 
neurotransmitters like glutamate which upon activation can trigger inflammatory 
responses in microglia (Domercq et al., 2013; Pocock and Kettenmann, 2007). 
Activated microglia release inflammatory cytokines (Smith et al., 2012) most of which 
are regulated by NF-κB activation (Hayden et al., 2006) and TAK1 is an upstream 
modulator of NF-κB (Sato et al., 2005; Shim et al., 2005). Furthermore, it has been 
revealed that status epilepticus results in oxidative stress (Folbergrova et al., 2016) 
and oxidative stress has been shown to activate TAK1 (Onodera et al., 2015). In 
addition it has been suggested that hippocampal depolarized neurons can release 
TNF-α (Renauld and Spengler, 2002) which again activates TAK1 (Takaesu et al., 
2003). Previous studies confirm the findings of the present study and it can be 
concluded that TAK1 is activated in microglia after status epilepticus. 
 
6.2.3 Microglia-specific TAK1KO mice 
To further explore the role of TAK1 in epileptogenesis, microglia-specific TAK1KO 
mice were used. In these mice TAK1 is conditionally knocked out by Cre-
recombinase fused to a mutant estrogen ligand-binding domain (Cx3cr1CreER) (Yona 
et al., 2013) expressed under the promoter of CX3CR1. For Cre-recombinase 
activation, the presence of the estrogen antagonist TAM is required. PCR analysis 
was performed to confirm and differentiate Cx3cr1CreER:Tak1f l/f l (TAK1KO) and 
Tak1f l/f l (Fig. 5.14). In Cx3cr1CreER:Tak1f l/f l and Tak1f l/f l mice, TAM (1 mg / mouse) was 
injected two times a day for 5 consecutive days. As microglia are phagocytic 
descendants of the mesoderm, which migrate into the brain during embryonic 
development (Vilhardt, 2005), and because of their longevity and self-renewal, these 
cells persist throughout life of the organism without any input from peripheral 
immune cells. Therefore, three weeks after TAM administration TAK1 remained 
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knocked out only in CNS microglia (Goldmann et al., 2013), as peripheral immune 
cells in which TAK1 was knocked out due to TAM presence could be replaced by 
new cells after short time. After three weeks these mice were used for the 
experiment. 
 
6.2.4 Inflammatory response is reduced in TAK1KO 
animals 
It has already been revealed that in experimental autoimmune encephalomyelitis 
(EAE) microglia-specific TAK1KO mice showed strongly diminished CNS 
inflammatory responses including abolished activation of NF-κB, reduced expression 
and / or release of inflammatory cytokines like IL-1β, TNF-α and chemokines like 
CCL2 (Goldmann et al., 2013). Therefore, to investigate CNS inflammatory 
responses in microglia-specific TAK1KO mice in a mouse model of epilepsy, 
immunofluorescence staining for Iba1 was performed. The sections used for staining 
were obtained from animals perfused 5 d after status epilepticus induced by 
unilateral intracortical kainate injection. Immunofluorescence staining revealed 
reduced alteration in microglia morphology (hypertrophic cell bodies and processes) 
in microglia-specific TAK1KO mice as compared with their control littermates (Fig. 
5.14A). Furthermore, the transgenic animals showed significantly reduced Iba1 
immunoreactivity when compared to the Cre-negative controls (Fig. 5.14B). 
Moreover, the number of microglia was significantly lower in the hippocampi of 
microglia-specific TAK1KO mice compared to their controls (Fig. 5.14C). Microglia 
rapidly respond to noxious stimuli and are activated at a very early stage after an 
injury or infection (Cherry et al., 2014; Rock et al., 2004). In previous studies, 
activated microglia have been observed in animal models of epilepsy (Avignone et 
al., 2008; Eyo et al., 2014) as well as in brain tissue obtained from TLE patients 
(Beach et al., 1995; Najjar et al., 2011). Microglia activation is characterized by 
increased proliferation, morphological transformation and migration to the site of 
injury (Domercq et al., 2013). The significantly lower number of microglia in the 
conditional TAK1KO was presumably due to reduced proliferation and / or migration 
of the cells (Fig. 5.14C). In an EAE study, strongly diminished CNS inflammation and 
reduced tissue damage was found in microglia-specific TAK1KO mice (Goldmann et 
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al., 2013). Additionally, in the same study a significant reduction in NF-κB activation 
and inflammatory cytokines were observed in the transgenic animals (Goldmann et 
al., 2013). In an Experimental Subarachnoid Hemorrhage (SAH) study, TAK1 
inhibition via its specific inhibitor 5Z-7-oxozeaenol (Ninomiya-Tsuji et al., 2003) 
resulted in diminished SAH-induced apoptosis, reduced NF-κB activation and 
translocation to the nucleus, and decreased phosphorylation of p38 and JNK (Zhang 
et al., 2015).  
 
Altogether, it can be concluded that TAK1 deletion in microglia resulted in a reduced 
CNS inflammatory response. 
 
6.2.5 TAK1 deletion in microglia can reduce chronic 
seizures 
It has been suggested that inflammation promotes seizure generation based on the 
observations made in experimental animal models of epilepsy (Auvin et al., 2010; 
Balosso et al., 2008; Dube et al., 2010; Patterson et al., 2015) and outcomes of 
clinical studies (Choi et al., 2011; Haspolat et al., 2002; Tutuncuoglu et al., 2001; 
Virta et al., 2002b). In the present study, a reduced inflammatory response has been 
observed in microglia-specific TAK1KO mice 5 d after status epilepticus (section 
5.2.4). 
 
To investigate if the observed reduced inflammatory response in microglia-specific 
TAK1KO mice influences the seizure frequency in a mouse model of epilepsy, EEG 
recordings with video monitoring were made for one month after kainate-induced 
status epilepticus in TAK1KO and control mice. EEG recordings revealed that the 
average number of seizures / day was significantly lower in microglia-specific 
TAK1KO mice than in Cre-negative littermates (section 5.2.5; Fig. 5.15A). 
Furthermore, the average seizure frequency decreased in microglia-specific 
TAK1KO mice and increased in control littermates throughout the observed course 
of epileptogenesis (section 5.2.5; Fig. 5.15B). Inflammation and inflammatory 
cytokines have been suggested to promote epileptogenesis (Vezzani, 2014; Vezzani 
and Viviani, 2015). IL-1Ra, a member of the interleukin 1 cytokine family and a 
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natural inhibitor of the pro-inflammatory cytokine IL-1β, has been shown to exert 
potent anticonvulsant effects in various models of epilepsy (Auvin et al., 2010; 
Vezzani et al., 2002), and transgenic mice overexpressing IL-1Ra have been shown 
to be less sensitive to bicuculline-induced seizures (Vezzani et al., 2002). Moreover, 
VX-765, an inhibitor of IL-1β biosynthesis, was demonstrated to reduce chronic 
epileptic activity in a dose dependent manner after intrahipocampal injection of 
kainate (Maroso et al., 2011). Increased levels of IL-1β were observed in rats that 
developed epilepsy after EFSs (Dube et al., 2010). Furthermore, IL-1β administration 
has been shown to increase seizure susceptibility and seizure generation in animal 
models of epilepsy (Balosso et al., 2008; Dube et al., 2005). Moreover, 
polymorphism in the gene for IL-1β in humans has been linked to increased risk for 
FSs (Virta et al., 2002a). The bacterial endotoxin LPS was shown to cause CNS 
inflammation, microglia activation and release of inflammatory cytokines (Bossu et 
al., 2012; Qin et al., 2007).  Administration of LPS has been shown to increase 
seizure susceptibility and proconvulsant activity (Auvin et al., 2010; Galic et al., 
2008; Sayyah et al., 2003). 
 
It has been revealed that IL-1β and TNF-α inhibit glutamate reuptake (Hu et al., 
2000; Zou and Crews, 2005) and increase glial glutamate release (Bezzi et al., 
2001), which can subsequently increase neuronal excitability (Vezzani and Granata, 
2005). Moreover, glutamate release from glial cells activates slow inward currents, 
which might generate epileptiform activity through synchronization of pyramidal 
neurons of the hippocampus (Carmignoto and Fellin, 2006). Inflammatory cytokines 
also have been suggested to increase hyperexcitability and promote seizure 
generation by directly regulating neuronal activity (Vezzani and Viviani, 2015). IL1-β 
increases neuronal hyperexcitability (Zhang et al., 2008; Zhang et al., 2010)  via 
mediating NMDA receptor activity (Viviani et al., 2003; Yang et al., 2005) through 
phosphorylation of the NMDA receptor subunit 2b (NR2B), which increases Ca2+ 
influx (Viviani et al., 2003). TNF-α promotes hyperexcitability by increasing trafficking 
of GluR2-lacking AMPA receptors, which enhances Ca2+ influx (Beattie et al., 2002; 
Stellwagen et al., 2005) and reduces inhibitory transmission through endocytosis of 
GABA-A receptors (Stellwagen et al., 2005). Furthermore, in response to IL-1β 
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astrocytes generate and release vasoactive substances like VEGF, which increase 
BBB permeability and promote leukocyte infiltration (Argaw et al., 2009; Argaw et al., 
2012). As a result of inflammation, the BBB is disrupted resulting in hyperexcitability 
via reduction in glutamate uptake and K+ buffering by astrocytes (Vezzani, 2014). In 
addition, a positive correlation between BBB leakage and frequency of spontaneous 
seizures has been reported (van Vliet et al., 2007).  
 
Together, it can be concluded that TAK1 deletion in microglia can lead to reduced 
inflammatory responses, which might result in reduced chronic seizure generation. 
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7 Summary 
Previous studies provided evidence that FSs in children increase the risk of epilepsy 
development. EFSs in animals confirmed this assumption.  EFS generated with only 
hyperthermia induction caused astrocyte uncoupling, which was mediated by both 
reduced protein expression and alteration in the phosphorylation state of Cx43. 
These findings provide a mechanistic link between FSs and the development of 
epilepsy. EFS-induced inhibition of interastrocytic communication might be the 
consequence of inflammation via microglial activation. Astrocyte uncoupling occurs 
in the absence of neuronal death and astrogliosis, which suggests that these 
different aspects of astrocyte pathology are not mechanistically linked. EFSs 
generated with hyperthermia preceded by inflammation (DH experiments) did not 
increase the astrocyte uncoupling and did not influence the incidence of epilepsy. 
 
There is increasing evidence suggesting that inflammation promotes 
epileptogenesis. TAK1 deletion and inhibition have been shown to reduce 
inflammation. TAK1 activation was investigated in astrocytes and microglia at 
different time points after status epilepticus. TAK1 was found to be activated in 
microglia, but not in astrocytes, in a time-dependent manner after status epilepticus. 
Therefore, in the second part of the study the role of inflammation in epileptogenesis 
was investigated via TAK1 deletion in microglia. TAK1 deletion in microglia resulted 
in reduced CNS inflammation. In microglia-specific TAK1KO animals the frequency 
of chronic seizures was significantly reduced. TAK1-dependent cytokine release 
from microglia, but not from astrocytes, might be involved in epileptogenesis.  
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8 Perspective 
Epilepsy is a chronic brain disease and it affects two percent of the population. In the 
present study EFSs were investigated as a consequence of glial dysfunction which 
showed astrocytes and microglia respond to HT-treatment in different ways. To 
better understand FSs, it is needed to investigate the glial cell responses in the 
chronic phase. Moreover, to explore the activation of the NF-κB pathway followed by 
the production and release of inflammatory cytokines like IL-1β and TNF-α from 
specific glial cell types after EFSs, immunofluorescence staining should be made 
with cell specific markers. In addition to connexins, the activity of AQP4 and Kir1.4 
channel should also be investigated after EFSs. As glutamine synthetase along with 
the glutamate transporters EAAT1 and EAAT2 have been implicated in 
epileptogenesis, the function of these molecules should be studied after EFSs. 
Furthermore, EEG recordings should be made for small durations at different time 
points after EFSs throughout the life time of animals to predict more accurate the 
incidence of epilepsy development. 
 
Inflammation has been suggested to be involved in epileptogenesis. In the present 
study it has been shown that reducing inflammation via TAK1 deletion resulted in 
less chronic seizure generation. This finding should be confirmed by using TAK1 
inhibition via its specific inhibitor 5Z-7-oxozeaenol. Moreover, it should be 
investigated which of the downstream targets of TAK1 are involved in 
epileptogenesis. NF-κB activation and release of inflammatory cytokines should be 
quantified after TAK1 deletion and inhibition. Also the number of animals should be 
increased to study chronic seizure generation via EEG recordings. In addition, 
neuronal degeneration and regeneration should be investigated in acute as well as 
chronic phases. 
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